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Abstract 
Split Thickness Skin Grafting (STSG) is a well-known and established procedure for healing burn 
wounds throughout the world.  The procedure requires the removal of the epidermal and part of the 
dermal layer of the skin.  It leaves intact the deep reticular dermal layer which is known as the donor 
site, and has sufficient cells to regenerate the excised superficial layers.  STSG provides wound 
closure and accelerated healing for the burn wound, and there is great importance surrounding the 
success of graft take and scar management thereafter (Demirtas et al, 2009; Atiyeh et al, 2002). 
 
The presence of donor sites, though created to assist healing of the burn site, in fact creates an 
additional wound for the patient which often causes further psychological stress at a traumatic time 
in the healing process (Andrews, Brown, Drummond, & Wood, 2010). Donor sites are consistently 
identified as a particularly painful wound by burn patients. Pain associated with burn surgery has 
been shown to delay the patients return to work and daily functional activity (Wisley et al, 2010; 
Druery et al, 2005; Brown et al, 2008). Thus, protection of the remaining epidermal and dermal 
elements of this surgical wound (donor site) is required to assist effective tissue healing with minimal 
scarring. 
 
One intervention that may accelerate healing and reduce scar formation is the use of Interim 
Pressure Garment Therapy (IPGT) which applies 4 – 6mmHg of pressure to the thigh. This treatment 
has been utilised at a major Australian burns unit in Queensland by Occupational Therapists. 
However, this has involved inconsistent application with a focus on securing wound dressing rather 
than scar management. Despite this, anecdotal and observational evidence suggests that pressure 
therapy also makes a difference to some patient’s scar outcomes for donor sites. It is hypothesised 
that IPGT may improve postoperative management of donor sites through the application of a low 
superficial pressure that mimics normal skin tension, possibly preventing donor wound distension 
and subsequent micro-tears in the newly forming epidermis. Furthermore, this may reduce the 
effects of the inflammatory response, which may in turn give rise to a hypertrophic scar response in 
the later stages of the healing process. 
 
This research focuses on a unique area of burns donor site scar management. It is designed to test 
a low pressure tubular support garment as an intervention for the support of, and reduction of donor 
site scarring.  No known studies of this nature have been carried out to date, suggesting there is a 
need for rigorous clinical evidence to support the use of these garments for donor site scar 
minimisation. Thereby, two studies were undertaken. The objective of the first study was to 
determine the pressure range (mmHg) applied by the Interim Pressure Garment Therapy (IPGT). 
Forty seven healthy adult volunteers were measured and fitted with a pair of Interim Pressure 
Garments (IPG).  
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The garments were made onsite from a tubular knit material, similar in style to that of a support pant. 
In the absence of a consistent sizing chart for the reliable fitting of the IPG, a multiple regression 
analysis was used to design a sizing guide, with the aim of ensuring a standard pressure was applied 
to the thigh at the first fitting. The amount of pressure beneath the IPG was then determined using a 
thin pressure sensor pad of the Pico Press®, positioned under the garment on the thigh. The sensor 
was placed at the same height anatomically for each participant. The interim garments provided a 
range of 3 to 5.8 mmHg on the donor site thigh locations. This pressure range is low in comparison 
to other pressure garment therapies (10 - 40 mmHg) that have been reported to have an effect on 
burn scar formation (Quinn et al, 2010; Engrav et al, 2010). Obtaining these measurements assisted 
in establishing a baseline size chart for the consistent fitting of the interim garments for the main 
study. 
 
The second study was designed as a single centre, single (assessor) blinded, randomised, control 
trial in patients with burns donor sites to their thigh.  Patients were randomly allocated into a control 
group (with no pressure to donor sites), and an experimental group (with Pressure to donor sites) as 
the comparative treatment.  Groups were compared at baseline regarding the important prognostic 
indicators – age, donor site location, depth, size, and time since graft.  The IPGT was administered 
post-operatively between days 3 to 8 and was dependent on wound review and patient pain.  Patients 
were asked to continue to wear the pressure garment 23 hours per day for a period of 8 weeks, and 
were given 2 pairs of pressure garments. Follow up assessments and garment replacement were 
carried out fortnightly for a period of 2 months. 
 
Donor site wound healing was measured using the following tools; a high frequency, high resolution 
ultrasound scanner which objectively captures and reproduces skin thickness (Dermascan-C ®),  a 
self-contained and battery operated device which provides objective measurements of erythema and 
melanin based on the light absorption characteristics of human skin (DSM II ColorMeter ®), and The 
Patient Observer Scar Assessment Scale (POSAS) which measures scar qualities using a range of 
indicators such as pigmentation, pain, and overall scar appearance.  In this study, data were 
collected for eight patients and is presented as a pilot for this thesis. The results indicated a trend 
towards a decrease in donor site scar thickness over time for the IPGT group, compared to the 
control group. 
 
Overall, the results from these studies support the hypothesis that the application of IPGT as a 
treatment for burns donor sites may support donor site healing and consequently reduce scar 
thickness. However, continuation of this research will be required to consolidate this evidence and 
therefore, the limitations and future directions of the studies are discussed. 
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CHAPTER 1. INTRODUCTION 
 
1.1 Problem Statement 
Split Thickness Skin Grafts (STSG) are a common surgical technique for wound management, 
nonetheless evidence for the effective management of the donor site wound and associated 
symptoms remains inconclusive with little consensus on the ideal treatment to promote healing 
(Demirtas, Yagmur, Soylemez, Ozturk & Demir, 2010; Markl et al, 2010; Atiyeh, Al-Amm and Nasser, 
2002; Läuchli et al, 2013; McBride, Kimble, Stockton, 2014). Donor site wounds may have adverse 
consequences for the patient such as symptoms of pain and itch, and infection that can dramatically 
impact daily living (Gibran, Boyce & Greenhalgh, 2007; Carrougher et al, 2013). Furthermore, all 
donor sites have been identified as being at risk of scarring (Batkin & Maitz, 2013) and donor scarring 
has been found to take at least 12 months post-harvest to resemble normal skin (Nedelec, Correa, 
de Oliveira, LaSalle & Perrault, 2014). Thus the management of the donor site is as important as the 
skin graft itself.  
 
1.2 Preventative Management 
Decision making regarding the management of the donor site wound may be influenced by factors 
such as the patient’s level of comfort, pain and itch, the presence of leaking exudate, the speed of 
wound healing and treatment costs (Läuchli et al, 2013). Tissue support of donor wounds is essential 
to maximise healing, and there are numerous papers documenting the benefits and limitations of 
different donor healing methods including dressings such as hydrocolloids, silver impregnated, 
impregnated gauze, alginates, and negative topical pressure therapy such as VAC dressings 
(Bollero et al, 2010; Schintler, 2012; Demirtas et al, 2010; Markl et al, 2010; Martin et al, 2013). 
Despite this, a ‘gold standard’ of dressings for donor sites is lacking (Geary et al, 2012; Lyall & 
Sinclaire, 2000). McBride et al (2015) identify possible reasons for this:  
 
1. donor wounds are not usually the focus of treatment for a burns patient; 
2. treatment is concentrated on the grafted site with the donor site a second priority; and,  
3. finally, despite knowledge that a moist healing environment promotes epidermal regrowth, 
evidence surrounding dressing preference for donor wounds is lacking.  
 
While dressings are integral to donor wound recovery, other factors to facilitate scar maturity include 
treatment methods that reduce skin tension (Widgerow, Chait, Stals & Stals, 2000). This reduction 
in skin tension may be one of the actions of IPGT. 
 
Cost effective interventions for dressings that accelerate healing and reduce scar formation of donor 
site wounds are common across the literature (Gibran et al, 2007; Mcbride et al, 2015) however, no 
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studies have been identified to date that specifically investigate pressure garment therapy for this 
purpose.   
 
As an adjunctive treatment, low level pressure therapy in the form of tubular support bandages may 
have an integral part to play following donor site harvest. Arem and Madden (1976) found wounds 
that heal under tension display increased scarring. This has been supported by Atkinson, McKenna, 
Barnett, McGrath and Rudd (2005) who utilised adhesive paper tape to decrease skin tension on 
surgical scars and found it effective in the prevention of hypertrophy of these scars. Widgerow et al, 
(2000) also discussed the benefits of tissue support to counteract the forces of tension on a healing 
scar. Similarly, Rose and Deitch, (1985) and Judge, May and De Clement (1984) have presented 
findings that supportive pressure (10 – 20mmHg) from tubular bandages reduced the incidence of 
hypertrophic scarring of burn grafts (when the tubular bandages were applied prophylactically in the 
immediate post-operative phase). Engrav et al (2010) also undertook a 12 year study investigating 
custom pressure garment effectiveness also on hypertrophic post burn scars. Two groups of 
pressure garments were tested; a low pressure group (of 5 mmHg) and a normal pressure group of 
17 – 24 mmHg pressure. The findings indicated that moderate to severe burn scars and grafts were 
significantly thinner, softer and had a better overall appearance after the application of normal 
pressure therapy. Furthermore, a significant difference has been reported regarding the thickness of 
burn scars that were preventatively treated with pressure of 15mmHg when compared to mean 
pressure of 10 mmHg (Van den Kerckove et al, 2005). All of these results imply that a higher pressure 
(for example above 10mmHg) is required to improve scarring. However all of these studies, 
assessed the effect of pressure on burn scars or grafts which are generally deeper wounds than 
donor sites. The differences and similarities of these two wounds are discussed in Chapter 2 of this 
thesis, in addition to the concept that a more superficial donor site wound may benefit from a gentle 
supportive pressure for scar minimisation.   
 
For the purpose of this thesis, low level pressure therapy for donor site wound support and scar 
minimisation is classified as less than 10mmHg, while standard pressure therapy for the treatment 
of hypertrophic scarring to burned and grafted sites is classified between 10 to 25mmHg.  
 
1.3 Significance of the research 
The research presented in this thesis aims to provide a better understanding of the effects of low 
level pressure therapy specifically on donor site healing which is currently poorly represented in the 
literature. If low level pressure therapy is in fact shown to improve donor site healing, it is anticipated 
this outcome will further enhance patient comfort, provide the patient with a better cosmetic outcome, 
reduce the incidence of abnormal scarring and reduce the associated psychological stress (Ripper, 
Renneberg, Landmann, Weigel, & Germann, 2009).  
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Additionally, such an outcome may allow the healed donor site to be re-harvested for STSG in burn 
patients with large TBSA burns and limited donor site availability.  
 
If low level pressure therapy is shown to make no difference to donor scar healing, this outcome may 
change the clinical practice in centres that currently apply pressure therapy to donor sites. It will 
provide valuable information for decision making to contain escalating burns scar management costs 
for the Occupational Therapy Department where the research was conducted. 
 
1.4 Aims of the research 
The overarching aim of this research is to determine whether the pressure exerted by IPGT is 
effective to support burn donor site healing.  As part of this research a theoretical basis for the mode 
of action of IPGT to support the donor wound and reduce scarring is proposed; this being the 
provision of gentle tissue support of the microcirculation and interstitial tension reduction in a new 
superficial wound which is discussed in detail in chapter two of this thesis. 
 
There are six main aims of this research; 
1. To discuss the theoretical basis and hypothesis for pressure therapy donor site wounds.  
2. To introduce the concept of low level pressure garment therapy (4 – 6 mmHg) for tissue 
support and scar minimisation of superficial donor wounds.  
3. To determine and standardise the pressure range (mmHg) applied to the thigh by IPGT.   
4. To design a study protocol for a clinical trial that aims to test the effectiveness of these 
garments for donor site scar minimisation.   
5. To undertake a pilot study to improve the quality and efficiency of data collection, and 
identify deficiencies in the design of the study protocol. 
6. Finally, to disseminate the theory of low pressure support for further discussion and 
testing in the hope it may improve donor site management in the future. 
 
These aims are discussed in the chapters that follow. 
 
1.5 Overview of Chapters 
The thesis is written in a hybrid style, combining chapters and journal papers currently prepared for 
submission or submitted and under review for publication. Chapters presented as publications under 
submission include a preamble describing the relevance of the content to this thesis. A brief overview 
of each chapter is as follows. 
 
Chapter 2 provides an overview of the anatomy of the skin and the wound healing process for normal 
healing. Select factors that affect wound healing and cause abnormal scarring are identified (such 
as TGF-β) and discussed in relation to increasing interstitial wound tension.  
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It is acknowledged however, that wound healing involves an extremely complex process of 
interactions from a multitude of factors that are challenging to discuss in relation to this particular 
thesis. The use of low level pressure therapy to counteract interstitial wound tension but support 
wound healing and consequently scar reduction for donor sites is explored.  Therefore, it is important 
to emphasise that this chapter presents wound healing from a therapists scar management 
perspective rather than a scientific one. 
 
Chapter 3 introduces IPGT as a novel low level pressure treatment for donor site management. The 
chapter includes a discussion of the role of the medium to high level pressure garment therapy (15 
– 45 mmHg), currently promoted as the ideal pressure for burns scars and grafts. The study 
presented in this chapter was undertaken to establish the pressure range provided by the IPGT, 
which was previously unknown, in addition to providing a sizing chart.  
 
Chapter 4 outlines a Study Protocol for future research: a randomised controlled trial testing the 
effectiveness of a low pressure tissue support pant (3 – 6 mmHg) on burn donor sites. It includes a 
literature review of current trends for donor site scar management and outlines the rational for 
investigating IPGT as a potential tissue support treatment for donor site scar management. The 
protocol presents the aims and methodology of the main study, including study design, and 
properties of the data collection tools utilised. The two participant groups (pressure garment and no 
pressure garment) are described, and sampling and inclusion/exclusion criteria are provided. Finally, 
the procedure and proposed data analysis are described in depth.  
 
Chapter 5 outlines the pilot study that was undertaken to test the aims of the study protocol outlined 
in Chapter 4. The pilot study aims are outlined, the results of the pilot study are discussed, the quality 
and efficiency of data collection are reviewed and the limitations in the design of the main study are 
discussed. Finally the clinical utility of the Dermascan C® in a busy clinic environment is raised. 
 
The final chapter (Chapter 6) summarises the preliminary results and clinical reasoning behind 
Interim Pressure Garment Therapy as a treatment for donor site scar management. It discusses the 
limitations of the research thus far, raises considerations such as the feasibility of using the 
Dermascan C ® for future studies from a practice perspective and proposes future directions for the 
investigation of low pressure tissue support in the prevention of donor scarring for the burns patient 
population.   
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CHAPTER 2: 
ANATOMY OF HEALING, MECHANICAL TENSION AND WOUND SUPPORT 
 
In order to understand how IPGT may affect a healing donor wound, it is important firstly to 
understand the function of skin, the processes that occur when the skin layers are damaged during 
the harvest of the donor site, and the progressions associated with regeneration of skin through to 
the formation of the donor scar. Thus, as mentioned in the previous chapter, this chapter gives an 
overview of the anatomy of the skin and the wound healing process. Wound healing is raised from 
a therapists scar management perspective rather than a scientific one. Whilst the use of IPGT is 
discussed largely in isolation as a treatment to reduce scaring, select factors that affect wound 
healing and cause abnormal scarring are raised (such as TGF-β).  These signalling mediators and 
factors associated with wound healing are briefly acknowledged in relation to increasing interstitial 
wound tension however, the complexity of these interactions falls beyond the scope of this thesis.  
 
Abnormal scarring is a potential complication of partial thickness burns which may be minimised with 
appropriate non-surgical techniques such as pressure therapy (Johnson & Richard, 2003), which is 
effective only while the scar is immature (Williams et al, 1998). Recognising there can be a variation 
in depth of donor site wounds, they can often involve partial thickness skin loss which is comparable 
in depth to partial thickness burns. While both should heal spontaneously within a 10 – 14 day period, 
the problems associated with wound healing of partial thickness burns are often shared with donor 
sites (Gibran et al, 2007).  Gibran et al (2007) states “The deeper the wound, the longer it takes to 
heal – increasing the risk of pain, infection and ultimately, scar formation”. Donor wounds however, 
are often overlooked as a potential scar concern despite evidence suggesting all donor sites are at 
risk of delayed in healing (due to infection, comorbidities) and abnormal scarring (Atiyeh et al, 2002; 
Batkin et al, 2013).  As partial thickness burns are frequently treated with pressure garment therapy 
(PGT) prophylactically for scar minimisation at the Royal Brisbane and Women’s Hospital, it follows 
that the application of pressure may assist in scar reduction for donor wounds.  Therefore, an 
explanation of how the application of low level pressure therapy (IPGT) may counteract interstitial 
wound tension and support wound healing for donor sites is now presented. 
 
2.1 Background of skin function 
The primary function of the skin is to act as a barrier (Singer & Clark, 1999). It provides protection 
from mechanical impacts and pressure, variations in temperature, micro-organisms, radiation and 
chemicals (Baum & Arpey, 2005). It regulates several aspects of physiology, including body 
temperature via sweat and hair, and changes in peripheral circulation and fluid balance via sweat. It 
acts as a reservoir for the synthesis of Vitamin D. Lastly, the skin contains an extensive network of 
nerve cells that gives the skin the ability to detect changes in the environment (Greenhalgh, 2007) 
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with separate receptors for heat, cold, touch, and pain. Any wounding to the skin, affects all the 
above functions of the skin (Tortora & Grabowski, 1993). 
 
2.2 Skin anatomy 
The skin is the largest organ of the body in surface area and weight (Tortora & Grabowski, 1993).  It 
is composed of three main layers; the epidermis, the dermis and the subcutaneous layer. 
The epidermis is the most superficial layer and is continually being regenerated.  Keratinocytes are 
the main skin cells of the epidermis. They are formed by cell division at the base of the epidermal 
layer and continually move towards the surface. As they move, they gradually die and become 
flattened. The flattened dead keratinocytes make up the very outer layer of the epidermis and are 
defined as the stratum corneum. This protective layer is continually worn away or shed. Melanocytes 
are cells that produce the pigment melanin that protects against UV radiation and gives skin its 
colour. 
Figure 2.1: Basic skin layers demonstrating sweat and sebaceous glands, hair follicles and nerves 
(Alexilus-medical/Shutterstock.com) 
 
The dermis is the second main skin layer that includes, hair follicles, the sweat glands (responsible 
in part for thermoregulation of the body via perspiration), and the sebaceous glands (produce sebum 
to keep hairs free from dust and bacteria). The subcutaneous layer under the dermis is made up of 
connective tissue and fat (Tortora & Grabowski, 1993). 
 
2.3 Wounds to the skin 
A wound is defined as a breakdown in the protective function of the skin. It may present with a loss 
of stability of the skin layers outlined above, with or without loss of underlying connective tissue (i.e. 
muscle, bone, nerves).  
 s33634065  7 | P a g e  
 
Variations in wound healing depend on the mechanism of injury. Injury to the skin or underlying 
tissues may be caused by surgery, disease, or trauma including friction/shear force, pressure, or 
chemicals, or temperature extremes such as burns. Appropriate management of the skin wound 
from symptom to resolution is a critical focus to restore the integrity of the skin, and maximise function 
and cosmetic outcome with the least amount of scarring possible (Greenhalgh, 2007). The focus of 
this thesis will be pointed toward discussing the processes of wound healing and scar formation to 
burn donor sites following a Split Thickness Skin Graft (STSG) procedure. 
 
2.4 Wound healing and burns 
2.4.1 Burns –modes of injury, classifications 
A burn is defined as a traumatic injury to the skin primarily caused by thermal or other acute 
exposures. Burns occur when some or all of the cells in the layers of skin are destroyed by heat, 
cold, electricity, radiation or caustic chemicals. Burns are generally acute wounds caused by an 
isolated, non-recurring insult (with the exception of repeated self-harm). They progress rapidly 
through orderly stages of healing (Orgill, Solari, Barlow & O’Connor, 1998). The progression of 
wound healing through these phases can be derailed by external influences such as tension on the 
wound (Widgerow et al, 2000). This can result in either insufficient healing or excessive scar 
formation. 
 
Wounds to the skin caused by burns heal in one of two ways, either by primary intention (surgical 
interventions such as split thickness skin grafts (STSG) or conservatively through secondary 
intention depending on the depth of the burn. Wounds that heal by secondary intention (such as skin 
graft donor sites) are left for the body to repair. These processes of wound healing through primary 
intention (surgical intervention) or secondary intention will now be briefly discussed. 
 
2.5 Surgical intervention of burn wounds 
2.5.1 Split Thickness Skin Grafting (STSG) 
When a burn penetrates deeply into the dermis of the skin, surgery is often required to assist healing. 
STSG provides wound closure and accelerated healing for deeper burn wounds. This procedure can 
assist in the minimisation of scarring and reduce the risk of infection through skin closure (Demirtas 
et al, 2009; Atiyeh et al, 2002). However, the process of skin grafting requires the removal of the 
epidermis and part of the dermal layer of healthy skin at an uninjured site - the donor site. The donor 
site usually has sufficient residual cells to regenerate the excised superficial layers of tissue however, 
scarring of the donor site may occur if excision is deeper than planned or if wound healing is delayed 
(Lauchli et al, 2013). The disruption of the integrity of the skin during STSG harvesting results in a 
new, often painful and unexpected wound for the patient (Demirtas et al, 2009).   
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Protection of the remaining epidermal and dermal elements of the donor site is required to assist 
effective wound healing with minimal scarring, reduced pain and itch (Muller, Gahankari & Herndon, 
2007; Ripper et al, 2009; Clark, Cheng & Leung, 1996; Bloemen et al, 2009; Gurtner, 2007; 
Carrougher et al, 2013; Atiyeh et al,  2002). 
 
2.5.2 The donor site 
Commonly, donor skin is surgically removed from the patient’s own thigh area, using a Dermatome 
at a measure of 8:1000 inch to 12:1000 inch (depending on the thickness required to heal the burn 
defect) (Muller et al, 2007). Donor sites taken from the thigh generally follow Langer’s lines of tension, 
and therefore the amount of directional pull from skin tension on the healing wound should assist to 
minimise scarring (Widgerow et al, 2000).  
 
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: Tension lines as drawn by Langer (1861)          Figure 2.3: Right anterior thigh donor wound day 
(Cited in Carmichael, 2014)   3 post-harvest following Langer’s lines 
                                                                                             (Photo courtesy RBWH consent obtained)  
2.5.3 Donor site regeneration 
The tissue removed for a STSG is comparable in depth to a partial thickness skin loss (Muller et al, 
2007) or second degree burn (Greenhalgh, 2007).  
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There should be enough residual epidermal cells in the remaining dermis of the donor site to allow 
re-epithelisation to occur over an approximate 14 day period (Singer & Clark, 1999).  Healing time 
however depends on the depth of donor skin removed (dependent on pressure applied by the 
surgeon’s hand, the vascularity of the donor site, the choice of wound management dressings such 
as alginates and hydrocolloids), in addition to patient factors such as age, skin type, and the 
presence of infection (Muller et al, 2007; Lauchli et al, 2013).  The risk of hypertrophic scarring 
increases for donor sites following the excision of deeper grafts (Batkin et al, 2013; Chittoria & Padi, 
2013). Despite the donor site depth being incredibly thin, patients often describe the pain from the 
wound feeling like ‘bad gravel rash’, and report worse pain in this wound than the original burn site 
(Wisley, Wilson, Duncan & Tarrier, 2010; Druery, Brown & Muller, 2005; Brown, McKenna, Siddhi, 
McGrouther & Bayat, 2008; Quinn, Wasiak & Cleland, 2010; Anzarut, Olsen, Singh, Rowe & Tredget, 
2009; Demirtas et al, 201; Markl et al, 2010). Red thickened scars can reduce physical function and 
create a distorted physical appearance for a burn-injured patient (Wisley et al, 2010; Druery et al, 
2005; Brown et al, 2008). 
 
2.6 Normal wound healing cascade  
While donor sites differ from burns scars and grafts in that they are surgically created, they also 
share similarities in the healing processes. After cutaneous injury, donor wound healing maintains 
the same complex and dynamic cascade of events as burns injuries. These can be viewed in four 
main stages: haemostasis, inflammation, proliferation (tissue formation) and tissue remodelling 
(Atiyeh et al, 2002).  
 
2.6.1 Haemostasis 
Haemostasis is the initial vascular phase following tissue injury, where mediators, platelet factors 
and coagulation begins (Widgerow et al, 2000). Vascular constriction causes local tissue blanching, 
the cessation of bleeding, and the formation of a clot consisting primarily of fibrin (a protein for blood 
clotting) and platelets (colourless blood cells that assist blood to clot). The formed clot not only 
contributes to haemostasis, but also serves as a temporary matrix for incoming inflammatory cells 
(Baum & Arpey, 2005). 
 
2.6.2 Inflammatory Phase 
Once bleeding of the donor site is controlled, the inflammatory phase begins and lasts around five 
days (Widgerow et al, 2000).  This stage is typically characterised by heat, swelling and pain due to 
capillary vasodilation and increased tissue permeability (Baum & Arpey, 2005).  Tissue permeability 
allows inflammatory cells (such as neutrophils, macrophages and lymphocytes) to migrate into the 
wound and stimulate systemic inflammation and growth factors. These growth factors are released 
by the clot and surrounding wound tissue in response to chemical and mechanical signals (Guo & 
DiPietro, 2010).  
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Inflammatory cells are involved in the clearance of invading microbes (such as bacteria) and cellular 
debris. They release cytokines which promote tissue regeneration by stimulating angiogenesis (the 
development on new blood vessels). In addition, they activate cells such as keratinocytes (the main 
skin cells) and specialised fibroblasts (myofibroblasts) that produce collagen to enhance wound 
closure (Guo & DiPietro, 2010; Li-Tsang et al, 2015). The myofibroblasts assist in the re-
establishment of structural integrity to the injured tissue however, excessive and irregular deposition 
of collagen by these cells can result in a thickened scar (Li-Tsang et al, 2015).  
 
If the inflammatory stage is suppressed, healing is delayed. Conversely, if there is an abundance of 
inflammatory mediators (such as TGF-β) and mast cells, then excessive scarring may ensue 
(Widgerow et al, 2000). Clinically mast cells release chemicals such as histamine which commonly 
results in itch for these patients (Gauglitz, Korting, Pavicic, Ruzicka & Jeschke, 2011), and TGF-β 
as an inflammatory mediator regulates collagen synthesis in scar formation, therefore a balanced 
inflammatory stage is essential for effective scar management (Widgerow et al, 2000).  
 
2.6.3 Proliferative Phase 
Following the period of inflammation, the proliferative phase commences and is characterised by the 
regeneration of the epithelium in addition to the migration of cells through the provisional wound 
matrix. This phase occurs between days 4 to 21 post injury (Cherry, Hughes, Kingsnorth, & Arnold, 
1994). The most prominent cell types are the fibroblasts (the principal cell of connective tissue) and 
keratinocytes (basic skin cells), both which support collagen formation and capillary growth (Guo & 
DiPietro, 2010; Greenhalgh, 2007). They form the temporary extracellular matrix (ECM) or 
framework that provides structural and biochemical support to the surrounding cells.  
 
Angiogenesis (the formation of new blood vessels) is a predominate feature of the proliferative 
phase. The ECM begins to be replaced by granulation tissue (new connective tissue and blood 
vessels) at approximately five days after injury (Singer & Clark, 1999). The newly formed blood 
vessels increase oxygen to the wound which decreases the fibroblast proliferation and signals the 
commencement of collagen production by the existing fibroblasts (Cherry et al, 1994). There are six 
types of collagen found within human skin (Cherry et al, 1994), with type III collagen at maximum 
synthesis around days 5 to 10 post injury (Kanzler, Gorsulowsky, & Swanson, 1986).  
 
Following the production of collagen, fibroblasts are associated with wound closure prior to their 
degradation thereafter. The fibroblasts produce myofibroblasts which have a similar property to 
smooth muscle tissue. The conversion of these cells occurs approximately at day 8 to 10 post injury. 
Myofibroblasts are responsible for applying tension to the tissue matrix which thereby contracts 
contributing to wound closure and commences the remodelling phase (Cherry et al, 1994; Guo & 
DiPietro, 2010).  
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2.6.4 Remodelling Phase 
Following rapid proliferation and ECM production, the healing process enters the remodelling phase. 
Many of the newly formed capillaries produced during angiogenesis regress so that vascular density 
in the area can return to normal, and the remodelled ECM can approach that of normal tissue. The 
main aim of this phase is to restore tensile strength to the scar and maximum collagen production 
occurs approximately two to three weeks post injury (Cherry et al, 1994). During this phase, the type 
III collagen fibres are replaced with more stable type I fibres that are cross-linked through covalent 
bonds (Bailey, Bazin, & Delaunay, 1973). The developing tensile strength of the scar is determined 
by the amount of cross linking between the type I collagen fibres, rather than the amount of collagen 
produced (Cherry et al, 1994). The damaged tissue (original donor wound) is thereby restored 
through the formation of the newly forming connective bonds and re-growth of the epithelium (Enoch 
& Price, 2004). The remodelling phase is a dynamic process whereby old collagen is re-absorbed 
and new collagen is synthesised (Bailey et al, 1973). Restoration of the balance between collagen 
synthesis and degradation can continue for up to two years following injury (Cherry et al, 1994; 
Rawlins, Lam, Karoo, Naylor, & Sharpe, 2006). 
 
If epithelisation of the wound takes longer than 14 to 21 days to occur, the wound is more likely to 
develop hypertrophic scarring than those wounds which heal more quickly (Deitch, Wheelan, Rose, 
Clothier & Cotter, 1983; Atiyeh, 2007; Macintyre & Baird, 2006; Bloeman et al, 2009; Sharp et al, 
2015). Therefore, the purpose of the STSG procedure for deep burns is to minimise the healing time 
in an attempt to reduce scarring (Cubison, Pape & Parkhouse, 2006). 
 
2.7 Factors affecting wound healing  
A review of the literature published over the past decade indicates the advances that have been 
made in understanding the process of wound healing and abnormal scar formation (Costa et al, 
1999; Gibran et al, 2007). In undamaged skin, fibroblasts are placed under a relatively low amount 
of interstitial tension due to the support provided by the surrounding stable collagen matrix.  
Conversely, when a fibrin clot forms in damaged skin, local growth factors stimulate fibroblasts from 
the surrounding intact dermis to enter this provisional matrix. These migrating fibroblasts, along with 
tiny blood vessels, fill the wound. Due to their influx, tension is increased within the confines of the 
wound. As fibroblasts continue to migrate into the new wound they exert tractional forces (or stress 
lines) on the developing structures around them (Tomasek, Gabbiani, Hinz, Chaponnier, & Brown, 
2002). At the same time, differentiated myofibroblasts produce collagen and other extracellular-
matrix (ECM) components that form the structural framework of the healing tissue. The development 
of this increased pressure (mechanical stress), further signals fibroblasts to develop additional stress 
fibres and consequently more collagen is produced to strengthen the wound in an attempt to reduce 
the increased pressure on the newly developing structure (Tomasek et al, 2002).  
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FIGURE 2.4: Model of the role of myofibroblasts during the healing of an open wound. 
Myofibroblasts and mechano-regulation of connective tissue remodelling (Tomasek et al, 2002) 
 
There are many other factors and signals associated with this complex process of remodelling not 
discussed here as they are beyond the scope of this thesis. However, the overall interactions of 
signals and factors results in a shortening of the collagen matrix with corresponding wound closure 
Fig (c). 
    
Figure 2.5: Scar remodelling (c) and scar closure - normal (d) versus thickened scar (e) (Tomasek et al, 
2002) 
 
When a normal healing wound closes, myofibroblasts disappear by apoptosis and a scar is formed 
(d). However, in abnormal scar formation, myofibroblasts continue to remodel the ECM, which results 
in connective-tissue contracture or thickened scar (e) (Tomasek et al, 2002).  
 
2.7.1 Mechanical forces influencing healing 
During the complex cascade of events that is wound healing, fibroblasts, myofibroblasts, endothelial 
cells, and epithelial cells are all affected by intrinsic and extrinsic mechanical stimulation (Agha, 
Ogawa, Pietramaggiori, & Orgill, 2011). Mechanical forces (such as tension, osmotic and hydrostatic 
pressure) produced by the developing ECM and extracellular fluid (ECF) impact on these cells and 
cause them to convert the mechanical stimuli into electrical or chemical signals (Agha et al, 2011).  
It is well documented that wounds healing with increased mechanical tension (caused by over active 
inflammatory mediators or poorly supported wounds) can form with increased scarring (Arem & 
Madden, 1976; Burgess,Garisson, Rand, Vossoughi, & Hollinger, 1990).   
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Strategies for nonsurgical interventions of scar reduction focus on counteracting the mechanical 
forces generated by the contracting wound (Harrison & MacNiel, 2008) and reducing the fibrotic 
response before abnormal scarring can occur (Ladak & Tredget, 2009).  
 
2.7.2 Mechanical Tension and Wound Support 
A single causative factor for abnormal scarring following wound healing has yet to be identified 
however, a commonly suggested initiating factor acting on the healing wound is tension (Atkinson et 
al, 2005; Harrison & MacNeil, 2008). Every phase of wound healing and remodelling is influenced 
by mechanical forces such as tension (Agha et al, 2011). For example, during the proliferative stage 
of normal wound healing, weak preliminary type III collagen fibres are replaced with strong closely 
woven type I fibres (Bailey et al, 1975; Clarke et al, 1996). However, if the wound is situated in an 
area of high physical tension (that is, against Langer’s lines), undue strain can be placed on the 
weak type III collagen fibres, thereby reducing the tensile strength of the scar (Widgerow et al, 2000). 
Consequently, additional type III fibres are produced in response as the scar attempts to regain its 
strength against the skin tension, resulting in scar hypertrophy (Atkinson et al, 2005). A compressive 
force applied in an opposite direction to the skin tension on the wound can prevent the development 
of abnormal scarring (Kim et al, 2015).  
 
2.8 Non – surgical interventions for scar reduction 
Properly interpreted, the clinical application of external supportive forces (such as pressure 
garments) may be useful to normalise tension and cellular function during tissue repair (Cummings 
& Tillman, 1992). It is thought that pressure creates a hypoxic environment that results in the 
impaired growth of myofibroblasts and inhibits factors that produce excess collagen (Li-Tsang, 2015; 
Anzarut et al, 2009). Despite the frequent use of pressure garments for scar reduction, the 
mechanisms of mechanical pressure and the way the pressure influences scarring is not fully 
understood (Anzarut et al, 2009; Li-Tsang et al, 2015) Furthermore, the ideal amount of pressure 
necessary to be effective on burn scars and grafts is unclear (Engrav et al, 2010).  
 
This thesis hypothesises that the application of a gentle superficial pressure that mimics normal skin 
tension may prevent donor wound distension and subsequent micro-tears in the newly forming 
epidermis. Furthermore, by limiting donor wound distension and reducing wound stress, externally 
applied pressure may reduce the effects of signalling mediators that can cause increased collagen 
production. Gentle supportive pressures applied externally to the donor site by a pressure garment 
may assist to normalise tension on the wound and prevent the development of abnormal scar 
formation.  
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2.8.1 Pressure garment therapy 
Pressure garment therapy has been used for over 40 years to reduce thickened burns scars and 
graft sites (Ripper et al, 2009; Bloemen et al, 2009; Macintyre, 2006; Anzarut et al, 2009; Chang, et 
al, 1995; Gladfelter, 2007; Watkins, 2010.)  Pressure is applied to the healed burn scar or graft with 
a firm elastic garment, and dissipates the intrinsic tension in the wound, consequently reducing the 
amount of scar tissue generated (Larson et al, 1971 cited in Harrison, 2008).  The definition of firm 
has been reported in the literature to be between 15 mmHg and 40 mmHg (Quinn et al, 2010; Engrav 
et al, 2010). It has been suggested (Kirsher, Shetlar, & Shetlar, 1975 cited in Harrison, 2008) that 
these pressures establish a hypoxic environment that reduces fibroblast proliferation and collagen 
synthesis. However, these pressures are all reported on burns scars and grafts, not donor sites. 
 
Although the exact mechanism of scar reduction under pressure garments remains under continuing 
investigation (Partsch, 2005), it is thought to be due to the garment gently restricting blood flow to 
the scar surface area through a constant external pressure to the skin surface (Ripper et al, 2009; 
Clark et al, 1996).  This pressure assists in apoptosis (programmed cell death), and the early 
arrangement of collagen and elastin fibres to represent normal tissue (Ladak & Tredget, 2009). 
Pressure garments appear to enhance the scar maturation process and if worn for a minimum of 20 
- 23 hours per day, also appear to inhibit the development of hypertrophic or abnormal scar tissue 
(Atiyeh et al, 2013).   
 
Mechanical pressure and burn scar formation has been recently presented in a study reviewing the 
effect of pressure on the histology of burn scars (Li Tsang et al 2015). Li-Tsang et al (2015) found 
significant differences in their pressure treated group of burn scars in the first three months of 
treatment. Ten histological samples were taken from subjects who wore 15 mmHg of pressure 
provided by an elastic garment for 23 hours a day for a period of three months. Their results 
demonstrated that mechanical pressure applied by pressure garments caused significantly more 
myofibroblast suppression, an inhibition of keratinocyte proliferation, the promotion apoptosis and 
improved collagen fibre alignment in burn scars and grafts than the non-pressure treated groups. 
Early published studies (Fujimori et al, 1968; Larson et al, 1971; Leung & Ng, 1971; Klöti & Pochon, 
1979) also discuss the benefits of their findings with regards to the application of prophylactic 
pressure to reduce skin tension and prevent hypertrophic scars. 
 
It is recommended pressure garments be applied as soon as the burn wound or graft has healed 
and can tolerate them (Klöti & Pochon, 1979) and furthermore should be worn until the burn scar 
has matured or become pale in colour, resembling normal skin (Bloemen et al,2009). This process 
of scar maturation is reported to take 18 to 24 months to complete, but can be longer in some cases 
(Quinn et al, 2010; Demirtas et al, 2010; Bloemen et al, 2009; Chang et al, 1995; Watkins, 2010).   
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Although it is a well-known treatment in reducing scar formation following a burn, the effectiveness 
of pressure has not been scientifically assessed on donor site scars (Quinn et al, 2010; Demirtas et 
al, 2006; Ripper et al, 2009; Macintyre, 2006; Anzarut et al, 2009; Chang et al, 1995; Gladfelter, 
2007; Watkins, 2010; Engrav et al, 2007; Partsch & Mosti, 2008).  
 
2.8.2 Interim Pressure Garments  
At the Royal Brisbane and Women’s Hospital (RBWH) burns unit, a lower pressure “interim” garment 
(termed Interim Pressure Garment, IPGT for this thesis) is often applied as a temporary supportive 
measure, largely to hold dressings in place in addition to early scar minimisation. IPGTs are applied 
in the first two to three weeks post burn or graft, whilst waiting for these sites to heal sufficiently 
enough to tolerate the higher level of compression garments generally used for the treatment of 
burns scars. IPGT is also applied to donor wounds in the first week post operatively to assist with 
holding dressings in place and for pain reduction post operatively. The interim garments for donor 
sites are made from a stretchy elastic material (similar in style to Lycra® cycling pants), and apply a 
gentle supportive pressure over the thigh and donor site areas. Through the course of clinical 
practice at the RBWH, it has been observed that IPGT appears to reduce donor site erythema and 
reported pain in some patients.  
 
Figures 2.6 (overleaf) shows a healed donor scar that has reduced erythema, possibly as a result of 
being supported by the IPGT and the unsupported distal hyper-vascular scar where the garment 
finished short.  Several possible reasons could be proposed for this florid appearance distally: 
hydrostatic pressure gradient, patient contamination, or the hand pressure exerted by the surgeon 
during harvest with the Dermatome. Alternatively, the effect could have been due to the interim 
pressure garment providing adequate tissue support to normalise cutaneous pressures and tension 
on the wound in the early stages of healing. Thus, interim pressure garment therapy (IPGT) may 
assist to reduce an overproduction of inflammatory mediators that can be associated with increased 
scarring to the proximal site. 
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      Figure 2.6: Donor showing where                     Figure 2.7 IPGT extended 
      the IPGT finished short  
 
2.8.3 Donor cosmesis, pain and pruritus 
Donor sites are generally a superficial wound and their creation, while necessary to aid healing of 
deeper burns, is often unexpected by the patient. This can give rise to additional physical and 
psychological issues associated with burn injury such as cosmesis, pain and pruritus (itching) 
(Druery et al, 2005; LaSalle et al, 2008; Carrougher et al, 2013). Donor sites have been shown to be 
significantly more erythematous than normal skin during healing at 6 and 12 months and do not 
return to normal skin colour for up to 12 months post-harvest (Nedelec et al, 2014).  
 
Pain associated with burn surgery has been shown to delay the patients return to work and daily 
functional activity, with donor sites consistently identified as a potential source of concern for burn 
patients (Wisley et al, 2010; Druery et al, 2000; Brown et al, 2008; Quinn et al, 2010; Demirtas et al, 
2006; Anzarut et al, 2009.)  Pruritus has been reported to be a common complaint for healing or 
healed burns and donor sites, and has impact on sleep, activities of daily living, quality of life, and 
psychosocial wellbeing (Carrougher et al, 2013; La Salle, Rachelska, & Nedelec, 2008).  
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The application of external pressure to reduce blood rush to the surface of the wound, particularly 
when the patient is mobilising, has also been reported to assist in the reduction of pain for these 
patients (Costa et al, 1999; Larsen & Futtrup, 1992). It is thought that the increased blood rush 
caused by gravity when standing stretches the fragile surface of the donor site wound, resulting in 
pain and increased inflammation (Wisley et al, 2010; Druery et al, 2005; Brown et al, 2008; Quinn et 
al, 2010; Demirtas et al, 2006; Anzarut et al, 2009.)   It could therefore be hypothesised that the 
protection of the epidermal and dermal elements of surgical wounds (such as donor sites) may assist 
in the reduction of pain and in effective tissue healing with minimal scarring (Muller et al, 2007; Ripper 
et al, 2009; Clark et al, 1996; Bloemen et al, 2009; Gurtner, 2007) and improved quality of life.  
However, a recent publication (currently In Press) by a research team in Australia has identified 
broader HRQoL outcomes to be a more distal measure, with sensory and physical indicators a more 
central theme for burn patients (Simons et al, 2016).  
 
2.8.4 Additional factors affecting healing 
Following a burn injury the body initiates a systemic inflammatory response, affecting the metabolic, 
cardiovascular, gastrointestinal and coagulation systems, which further complicates the wound 
healing process (Jelenko, 1970; Wilson, 1996). Other factors that may affect the healing of burn 
donor sites include skin type, co-morbidities such as diabetes, the potential for infections and 
smoking. The nicotine inhaled from smoking reduces nutritional blood flow to the skin as a result of 
vasoconstriction which can result in tissue ischemia and impaired wound healing (Silverstein, 1992).  
Additionally, despite the depth of harvest being set on the dermatome, pressure from the surgeons 
hand when harvesting can also deepen the wound.  
 
2.9 Summary 
The use of IPGT in the treatment of burns patients at the RBWH has been inconsistent. The focus 
has been on wound dressing rather than scar management, and the amount of pressure that the 
garments previously applied to the donor site was undefined.  The evidence to suggest that IPGT 
may make a difference to some patient’s scar outcomes in their donor sites is therefore anecdotal 
and observational. Therefore, the study presented in the following chapter was undertaken to 
establish the pressure range provided by the IPGT, in addition to a sizing chart. This information will 
be used to inform future clinical trials and centres that wish to routinely measure pressure beneath 
IPGTs.    
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CHAPTER 3: A PRELIMINARY STUDY 
Publication submitted to the Journal of Burn Care and Research 
 
As the IPGT garment application had been used primarily to support wound dressings rather than 
as a scar management technique and the pressure gradients in the IPGT had not been quantified, 
it was necessary to undertake the following preliminary study to firstly determine an evidence based 
fitting plan (rather than rely on clinician experience), and secondly to establish the pressures that 
are applied by the IPGT to the donor site. It is planned that the establishment of these two factors 
will provide baseline data to be used in a clinical trial that tests the efficacy of IPGT as a scar 
management technique, presented later in the thesis. Details of the study below are now discussed.  
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Michelle. L. Donovan, (B Occ Thy) 1, 4*, Associate Professor Jennifer Paratz, (MPhty, FACP, PhD, 
Grad Dip Medical Ed) 2, 4, Professor Michael. J. Muller, (MBBS MMedSci FRACS) 3, 4, Dr Claire 
Simpson, (BSc, PhD) 3, Zephanie Tyack (B Occ Thy Hons., PhD) 2 
 
1 Occupational Therapy Department, Level 2, Dr James Mayne Building, Royal Brisbane & Women’s 
Hospital, Herston, Queensland 4029, Australia. 
2 School of Allied Health Sciences, Gold Coast Campus, Griffith University, Queensland 4222, 
Australia. 
3 Professor Stuart Pegg Adult Burns Centre, Level 4, Dr James Mayne Building, Royal Brisbane & 
Women’s Hospital, Herston, Queensland 4029, Australia. 
4 Burns, Trauma & Critical Care Research Centre, University of Queensland, School of Medicine, 
Level 9, UQ Health Sciences Building, Royal Brisbane and Women's Hospital, Herston, 
Queensland 4029, Australia. 
5 Centre for Children’s Burns and Trauma Research, UQ-Child Health Research Centre Level 6, 
CCHR   Building, The University of Queensland, St Lucia QLD 4067 
 
*Corresponding Author 
Ms Michelle L Donovan, Occupational Therapy Department, Level 2, Dr James Mayne Building, 
Royal Brisbane and Women's Hospital, Herston, Queensland 4029, Australia. 
michelle.donovan@health.qld.gov.au  Ph.: +61 417 646 304 / Fax: +61 7 3646 7495. 
 
 
 
 
 s33634065  19 | P a g e  
 
Abstract 
Introduction: Interim pressure garments (IPGTs) made from a tubular knit fabric, may be used for 
early donor scar management and to promote wound healing. The pressure exerted by these 
garments has not previously been objectively measured.  The primary objective of the study was to 
determine the pressure range (mmHg) applied to the thigh by these garments.  The overarching 
purpose of the study was to standardise the range of pressure delivered, prior to the commencement 
of a clinical trial that aimed to review the effectiveness of these garments for donor site scar 
management.   
 
Method: This study was a cross sectional single centre design. 47 healthy volunteers who with no 
wounds to the thighs. Firstly, a consistent sizing chart was designed for fitting the IPGs that are 
similar in style to a pair of Lycra ® cycling pants. Secondly, the amount of pressure beneath the IPGs 
was determined using a thin pressure sensor pad of the Pico Press®, positioned under the garment 
on the thigh immediately after the initial application to healthy volunteers.   
 
Results: In a multiple regression analysis only the mid-thigh measurement was a significant 
predictor of the IPGT size (p < 0.001, p = 0.64 and p = 0.13, using the three garment sizes of ex 
small, small, medium and large). Using the mid-thigh measurements for fitting pressure garments to 
healthy adult volunteers (N = 47), the interim pressure garments provided a pressure range of 3 to 
7 mmHg on the donor site thigh locations.  
 
Conclusion: The small variability in the pressures provided by the IPG’s supported the ability of the 
garments and sizing method to provide a standard range of low pressure at the time of the initial 
application.   
 
Key Words: Interim Pressure Garment Therapy, Tubular Support, Donor Sites, Burns, Occupational 
Therapy 
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3.1 Introduction 
Interim Pressure Garments (IPG) have been prescribed by occupational therapists at an Australian 
tertiary teaching hospital for over 40 years in clinical areas such as burns. The term ‘interim’ 
represents a temporary support garment that can be worn in the initial stages of healing following 
burns and associated surgery.  The purpose of IPGT has been primarily for holding dressings in 
place, rather than for reducing scarring or pain management.  However, through the course of clinical 
practice, it has been observed that applying these garments prior to wound healing appears to 
improve healing of donor sites, and reduce donor site erythema, itching and pain in some patients. 
A possible mechanism through which these positive outcomes are achieved is by protecting the 
donor site during wound healing. This in turn may prevent or reduce scarring to donor sites, although 
evidence of the effectiveness of IPGT for these purposes is limited. The importance of research 
investigating the prevention of scarring in donor sites has been highlighted by a prevalence of 
hypertrophic scarring in donor sites of 34% in Australian patients with burns who undergo grafting 
(Batkin et al, 2013). 
 
Recent studies which review the effects of pressures (ranging from 10 to 15 mmHg) on hypertrophic 
burn scar tissue exist (Candy, Cecila, & Ping, 2010; Li-Tsang et al, 2015; Partsch, 2005; Ripper et 
al, 2009).  However, studies investigating the effect of low level pressure (i.e. below 10 mmHg) to 
support superficial wound healing are lacking. Thus studies of the effectiveness of low pressure 
tissue support for superficial wound healing and scar prevention may be of benefit.  However, prior 
to these studies being conducted further knowledge is required to standardise a sizing method and 
determine the level of pressure provided by IPGT.      
 
3.2 Primary Objective This study aimed to: firstly, standardise a sizing method for the fitting of IPGT 
in patients with donor sites in the post-acute period after skin grafting that were unhealed; and 
secondly, establish the pressure range provided by IPGT to thigh donor sites in the post-acute period 
after skin grafting that were fitted using the established standardised sizing method. It is 
hypothesised that the pressure required to support donor healing at the wound / garment interface 
will be less than that reported for other pressure garment therapies. 
 
3.3 Ethical Clearance  
Ethical approval was obtained from the Royal Brisbane and Women’s Hospital Human Research 
Ethics Committee (Approval No: HREC/09/QRBW/327), and from the University of Queensland 
Medical Research Ethics Committee (Approval No: MREC2010000356). The methods have been 
presented according to the STrengthening Reporting of OBservational Studies in Epidemiology 
(STROBE) statement (von Elm, 2008). 
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3.4 Methods 
3.4.1 Study Design. A cross sectional single centre design was used.  
3.4.2 Setting/Recruitment. Recruitment of participants was via a poster placed in the staff rooms 
of the PSPABC, specialist outpatient departments and the Occupational Therapy department of the 
RBWH. The study took place in a temperature controlled burns treatment room of the Occupational 
Therapy Department.  One fitting only was undertaken for each participant, with recruitment 
completed over a two week time period.  
3.4.3 Participants. Inclusion criteria were healthy volunteers who were employees of the hospital 
with no wounds to the thighs, no medical condition affecting circulation of the lower limbs, no sensory 
loss or changes to the lower limbs, male or female over 18 years of age, and ability to provide 
informed consent. Exclusion criteria included being a current patient at the hospital. Once eligibility 
was established, participants were approached by the principal investigator and an explanation of 
the study procedure was provided.  
3.4.4 Procedure. IPG’s were made onsite by Occupational Therapy Assistants (OTA) out of a 
tubular knit material (Tubigrip ®, Molnlycke Health Care Pty Ltd, Sweden), using standard fabric 
patterns for extra small, small, medium, and large sizes. Patterns were used to ensure the consistent 
measurements were fabricated for each size. The OTA was provided with onsite competency based 
training to ensure the consistent standard of production of IPG’s. This training was provided and co-
ordinated by a Senior OTA. A risk assessment document was developed in order to undertake the 
study to demonstrate how IPG’s meet the criteria for demonstrating “no harm” according to the 
Australian Therapeutic Goods Administration risk assessment process. The garment pattern, sewing 
instructions and wear and care instructions were included in that document (Appendix B). 
 
As the purpose of this study was to establish sizing data, the IPG were provided to participants for 
fitting purposes only.  The garments were not worn for any treatment as such, and therefore a wear 
time log was not required. Healthy volunteers were required to spend 15 minutes in the same 
temperature controlled clinical room, prior to being measured and fitted with a pair of IPG’s. A 
standard measuring tape was used to determine the mid-thigh, hip and waist circumference (in 
centimetres) of each participant. The waist circumference measurement was taken at the point 
where a lateral crease appeared when the patient was asked to lean laterally.  Likewise, the bony 
landmark of the iliac crest was used to locate the point for taking the hip circumference. The mid-
thigh circumference was established by locating the anatomical mid-point of the thigh between two 
bony landmarks (being the patella and iliac crest) using a tape measure. Participants were then fitted 
with an IPGT size based on clinical expertise of an experienced occupational therapist, as per 
standard clinical practice in the hospital where the study was conducted.  
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A thin pressure sensor pad (PicoPress®) was then positioned under the garment on the thigh whilst 
the participant was stationary (i.e. a static measurement) to determine the amount of pressure at the 
normal skin/IPGT interface. The pressure pad was placed under the garment with at least 10 cm of 
fabric proximal and distal to the pad. This brief fitting of the IPG enabled sizing and pressure data to 
be collected for use in further clinical trials.  
 
3.4.5 Outcome measures The Pico Press® Pressure Sensor (TT Medii Trade, Soleddet 15, DK 
4180 Soro) was used to measure the pressure beneath the IPGT in mmHg. The validity and 
reproducibility of the Pico Press® has been supported for measuring the pressure in mmHg beneath 
pressure garments (Mosti & Rossario, 2008; Partsch & Mosti, 2010). The device is comprised of a 
hand held monitor with an LCD screen. A 5cm diameter, 0.2mm thick sensor attaches to the device 
via a thin plastic tube which is calibrated prior to use. A USB cable can attach to the device and a 
PC to record and visualise the pressure readings taken during dynamic tests. The device can store 
10 static measurements consecutively. The sensor was placed in the same position on the right thigh 
for each participant. The position of the sensor was established by locating the anatomical mid-point 
of the thigh between the two bony landmarks of the patella and iliac crest using a tape measure.  For 
each participant the IPGT size was chosen by an experienced clinician and the pressure reading (in 
mmHg at the thigh garment interface) was recorded.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1a: PicoPress ® sensor and             
        device.  
 
Figure 3.1b: IPGT with sensor  
         and device showing 5mmHg 
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Three static measurements were taken for each participant.  The mean of the three readings was 
used for data analysis in this study. The reliability of the PicoPress (R) has been supported with 
mean coefficients of variation of 2.79, lower than coefficients of variation of the Kikuhime(R)  and 
SIGaT(R) pressure measuring devices (4.17% and 8.52% respectively), with measurements taken 
on the distal leg of healthy human subjects beneath a blood pressure cuff (Partsch & Mosti, 2010)".   
 
3.4.6 Bias Due to the potential inaccuracy in self report of comfort of fit, where all participants may 
not have been as equally perceptive and therefore the results may have been influenced by a 
reporting bias. The participant opinion was therefore not included in this study and only the physical 
objective measurements (circumferences and PicoPress ® pressures) were recorded, thus reducing 
reporting bias. All measurements from all participants that were taken were included in the study. 
 
3.4.7 Sample size estimation. G Power was used to determine a sample size estimate for the 
multiple regression analysis of the ability of three variables (mid-thigh, hip and waist circumferential 
measurements) to predict IPGT size.  Based on an anticipated large effect size (Cohen’s f2 = 0.35; 
Cohen, 1988), the use of three predictor variables, a power of 0.9, and p value of 0.05, 45 participants 
were required.  The anticipated large effect size was based on a Cohen's dz of 0.80 calculated using 
the finding of a significant relationship between thigh circumference and pressure in mmHg (p = 
0.01) in 14 normal human volunteers, and a t-value of 3.01" (Macintyre, 2007). 
 
3.4.8   Statistical analysis. Descriptive statistics were used to describe the demographics, Body 
Mass Index and anthropometric data of the volunteer sample including means and standard 
deviations, medians and interquartile ranges.  Data were screened for outliers, linearity between the 
predictor variables, and heteroscedasticity.  Multicollinearity was judged to be present if a correlation 
of 0.9 between at least one set of predictors was found as part of the regression analyses 
(Tabachnick & Fidell, 1996).  Multiple linear regression was used to examine the influence of mid-
thigh, hip and waist circumference measurements in centimetres on the size of the garment chosen 
by the researcher.  The assumption of normality was checked using the residuals of the model based 
on visual inspection of P-plots, histograms and scatterplots.  The Durbin Watson statistic was used 
to test the independence of errors.  The level of significance for all analyses was set at 0.05.  
Statistical analyses were performed using SPSS Statistics for Windows, Version 23.0.0.0 (Armonk, 
NY:IBM Corp.). 
 
3.5 Results 
All forty-seven healthy volunteers who offered their time, were deemed eligible to participate in the 
study, all of whom completed the study.  Table 1 presents the sample demographics.  No data were 
missing for the forty-seven participants.  There were no adverse effects to the participants resulting 
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from this study. Screening of the data and checking the residuals indicated that the assumption of 
normality and independent of errors was acceptable (Durbin-Watson value = 1.0).    
 
Table 3.1: Participant characteristics for the total sample and by gender 
Demographic All participants 
Mean (SD) 
Males 
Mean (SD) 
Females 
Mean (SD) 
 
n (%) 
Age 
BMI 
 
n = 47 (100%) 
35.95 (10.92) 
26.75 (5.12) 
 
n = 15 (31.91%) 
37.87 (11.40) 
24.64 (3.29) 
 
n = 32 (68.09%) 
35.06  (10.76) 
30.26 (6.36) 
 
In the multiple regression analysis with mid-thigh, hip and waist circumference entered as predictor 
variables, only mid-thigh circumference was a significant predictor of IPG size (p < 0.001).  The 
unstandardized regression coefficients presented in table 2 indicated that an increase of 0.11 of an 
IPG size occurred using a 1cm increase in thigh circumference compared to the smaller changes in 
the size of garment that occurred using a 1cm increase in waist or hip circumference. A summary of 
the results of the regression model are presented in Table 2.  Overall the predictor variables of mid-
thigh, hip and waist circumference accounted for 71 percent of the variation in the garment size (R² 
= 0.71, F (3, 43) = 38.66, p <0.001).   
 
Table 3.2: Summary of Multiple Linear Regression Analysis for Variables Predicting the size of 
Interim Pressure Garments  
 
Predictor variables B S.E. B β 95% CI p value 
Mid-thigh circumference  0.11 0.02  0.73  0.06 – 0.16 < 0.001* 
Waist circumference -0.01 0.01 -0.08 -0.03 – 0.02    0.64 
 Hip circumference  0.02 0.01  0.23 -0.01 – 0.04    0.12 
* p <0.05 
Note: B = unstandardized regression coefficient; β = standardised regression coefficient 
 
Following the results of the regression analysis, the mid-thigh circumference was chosen to fit the 
IPG for the purposes of monitoring pressure beneath the garments. Using the mid-thigh based sizing 
guide to fit the IPGT a relatively consistent median pressure was obtained across the sample as 
demonstrated in figure 3.2 and table 3.3. 
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Figure 3.2 The median and interquartile range of pressure (mmHg) of IPGT 
 
 
Table 3.3: IPGT sizing demographics and respective median pressure.  
Garment 
pattern 
size 
Number of 
participants 
fitted (%) 
Mid-
thigh 
pattern 
diameter  
 Mid-
thigh 
pattern 
circumf 
Patients Mid-thigh 
measurement cm 
(Mean ± SD; 95% 
CI) 
Patients 
mid- thigh 
fitting range 
cm 
Reduction
% 
Pressure  
mmHg 
Median(IQR) 
Ex Small n=11 (23.41) 16cm 32cm 48 ± 1.2; 47-49 cm <50 cm 6.4 % 4 (4-5) mmHg 
Small n=14 (29.78) 19cm 38cm 52 ± 1.1; 51-53 cm 50-54.9 cm 6.9 – 7.6% 5 (4-5) mmHg 
Medium n=13 (27.66) 20cm 40cm 60 ± 5.7; 55-63 cm 55-59.9 cm 6.6 – 7.2% 4 (3-5.8) mmHg 
Large n=9 (19.15) 22cm 44cm 64 ± 4.7; 59-69 cm ≥60 cm 7.3% 4 (3-4.5) mmHg 
 
3.6 Discussion To our knowledge this is the first study to determine the amount of pressure, and 
variability of pressure, provided by IPGT fabricated from tubular support bandages. The results 
indicated firstly, that the pressure applied in mmHg at the IPG/thigh donor site interface immediately 
after the first application, was low (3 to 5.8 mmHg) compared to prior studies reporting pressures 
beneath pressure garments used for scar management. Secondly, that there was minimal variability 
in the pressures recorded.  Thus a standard low pressure was obtained at the first application of 
these garments which supported the primary aim of establishing the pressure range provided by 
IPGT to thigh donor sites in the post-acute period after skin grafting that were fitted using the 
established standardised sizing method.   
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These results raise discussion regarding whether such low pressures could be effective to support 
wound healing of donor sites and thereby to minimise scar formation. The application of IPGT for 
donor site wounds is not represented in the literature. However, Tubular Support Bandages (TSB) 
(Judge et al, 1983) and Tubular Pressure Bandages (TCB) (Rose & Deitch, 1985) which closely 
compare to IPGTs have been reported as an effective treatment for the prevention of hypertrophic 
scars, in both skin grafted and spontaneously healed burns (Judge et al, 1983. Rose & Deitch 1985), 
but their effectiveness for donor site management has not been investigated. Whilst TSB and TCB 
are made from the same elasticised fabric as IPGT, the main difference between these products and 
IPGT is that they are provided ‘off the roll’ (Figure 3.4) rather than sewn from a pattern (Figure 3.5). 
It is difficult to make any conclusions regarding the effectiveness of tubular bandages as the two 
studies reviewed (Judge et al, 1983; Rose & Deitch 1985) had major methodological shortcomings. 
Neither study reported clearly how scarring was assessed, the time frames for fitting the tubular 
bandages varied, and how the pressure readings for each level being tested was not reported.   
 
To our knowledge there have been no recent high quality studies regarding the level of pressure 
applied by IPGT, TCB or TSB on donor sites or on the pressures necessary for optimal tissue support 
for donor wound healing to minimise scarring.  There is, however, evidence regarding the use of 
much higher pressure garments (15 to 30mmHg) for the purpose of treating hypertrophic scarring 
on burn scars and grafts. However, those higher pressures were applied to burn wounds and grafts 
at a later stage of healing (Macintyre & Baird, 2006; Li-Tsang et al, 2015; Yildiz, 2007; Costa et al, 
1999; Ripper et al, 2009; Bloemen et al, 2009; Chang et al, 1995; Anzarut et al, 2009; Gladfelter, 
2007) and on deeper wounds than donor sites thus the findings cannot be extrapolated to donor site 
wounds.  
           
Figure 3.3: TSB and TCB             Figure 3.4: Tubigrip pattern and pant 
‘off the roll’ 
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The authors theorise that the therapeutic action of a low pressure (3 – 6 mmHg) IPGT may be 
threefold. Firstly, by providing low pressure support that prevents distension of the new donor wound, 
for example from blood rush when mobilising. Wound distension may compromise the fragile tissue 
integrity of a new donor wound. Secondly, IPGTs may minimise scarring by preventing friction 
caused by dressings moving against the skin. IPGTs may act to reduce friction and shearing early 
in the post-acute period caused when the patients either move in bed or mobilise. At the hospital 
where the study was conducted IPGT were provided as early as day one post operatively if the 
patient was able to mobilise with  the primary purpose of  holding dressings in place which may have 
reduced shearing and friction. Thirdly, IPGT may provide tissue support by contributing to the 
restoration of normal microcirculatory pressures in the interstitial space in the preliminary stages of 
healing post donor wound creation.  
 
It is well documented that wounds healing under tension are associated with thicker scarring 
(Widgerow et al, 2010). The low pressure applied by IPGT may mimic normal skin tension and 
provide just enough support to normalise tissue pressures in new burn donor sites. By normalising 
the pressures associated with wound healing IPGT may prevent an over production of signals such 
as those produced by TGF-β, which amongst other functions is particularly involved in the way scar 
tissue reacts to mechanical forces (Ogawa, 2011; Liu, Wang, & Cao, 2004).  Chemical and 
mechanical signals released during the complex cascade that is wound healing, react to increased 
interstitial wound tension (Agha et al, 2011). Consequently an increase in collagen fibres sent in 
response to strengthen the developing wound can result in thickened scar formation in the later 
stages of wound healing (Atkinson et al, 2005; Widgerow et al, 2000).  
 
Anecdotally the first author has observed that IPGT’s applied early after the creation of donor sites 
improved comfort for patients by keeping their dressings still and improved the overall appearance 
of the scar. Tubular support bandages from which IPGT are made, have documented benefits for 
improving the appearance of the burn scars, improving comfort and preventing skin contracture 
(Judge et al, 1984; Rose & Deitch, 1985). As this study was a precursor to examining the 
effectiveness of IPGT for that purpose, further discussion of this point has been documented in a 
study protocol in chapter four of this Thesis. 
 
3.7 Limitations 
None of the participants in this study had donor site wounds or scars. Thus, further testing is 
recommended to confirm that the pressures obtained at the normal skin/ IPGT interface are similar 
to those obtained at donor site wound/IPGT interface.  However, based on the work of Nedelec et al 
(2014) who found that donor site scars are not significantly thicker than normal skin when assessed 
at 3 months post burn it is anticipated that pressures obtained at a normal skin/IPGT interface would 
be similar to those found at a donor site wound or scar/IPGT interface.  
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The pressures recorded were all obtained as static readings, and therefore cannot be generalised 
to the pressures obtained during dynamic movement, which should be investigated in future studies 
 
3.8 Implications for practice 
In the current IPGT study pressures were only measured once immediately after the first application 
of the garment, so the findings may not generalise to pressures beneath IPGT’s that have been worn 
for any length of time.  IPGT fabricated from tubular support bandages may be a cost-effective option 
(AU$20 per garment) for the management of burn donor sites prior to complete wound healing.  
 
The finding of very low pressures beneath IPGT (3 to 6mmHg) can inform testing of the effectiveness 
of IPGT’s which is now required to determine whether such pressures are effective in promoting 
wound healing and reducing scarring in donor sites post-burn. Furthermore, as pressures beneath 
custom-made pressure garments have been found to reduce over time with wear (Engrav et al, 2010; 
Van den Kerckhove et al, 2005), further research is required to establish pressures beneath IPGT 
reduce over time and the factors that contribute to this potential pressure loss.  Pressures beneath 
IPGT need to be monitored throughout trials to be able to make statements regarding the 
effectiveness of IPGTs.  This study has documented the pressure range that can be expected 
beneath IPGs to thigh donor sites using a sizing method designed for this study. The results can 
inform future clinical trials and centres that wish to routinely measure pressure beneath IPGTs.    
 
3.9 Conclusion 
This study demonstrated that the pressure applied in mmHg at the IPGT/thigh donor site interface 
was low compared to pressures documented from custom-made pressure garments. However, the 
objective of the study was met, in that a standard pressure range (mmHg) was obtained beneath the 
IPGT applied to the thigh for donor healing using a sizing method we developed based on thigh 
circumference.  This information will be used in future clinical trials of the effectiveness of these 
garments to minimise scarring and improve wound healing.  A study protocol for a future clinical trial 
is presented in the following Chapter Four.  
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CHAPTER 4: A STUDY PROTOCOL 
 
 
The planning of this protocol takes into consideration the sizing data previously discussed in Chapter 
Three, and the risk assessment listed in the appendices. Once the baseline data had been 
established in the preliminary study, planning for the intended randomised control trial to test the 
Interim Pressure Garment (IPGT) was undertaken. The paper presented in this chapter aims to 
provide a better understanding of the possible effects of IPGT on donor site healing and provides 
the protocol for the RCT.  
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ABSTRACT  
Background: Pressure garment therapy is well recognized and commonly used by clinicians in the 
treatment of burns scars and grafts. The pressures in these garments (20 – 30mmHg) can support 
scar minimisation and evidence is well documented for this particular application (Li-Tsang et al, 
2015; Candy et al, 2010).  However, pressure garment therapy specifically for burn donor sites which 
also scar, is not well documented. This study protocol investigates the impact of a low pressure (4-
6 mmHg) interim garment utilised for donor support by Occupational Therapists at a major burn 
centre in Australia. Manufactured on site, with a primary purpose to hold donor dressings in place, 
the aim of the interim pressure garment appears to have a secondary purpose. As a clinician, the 
author of this thesis noticed that patients who wore the low pressure garments to hold their dressings 
in place appeared to be have donor sites that were more pale, flat and less painful than those who 
did not wear them. The study protocol outlines a randomised controlled trial designed to test the 
effectiveness of this treatment on burn donor scars.   
 
Methods/Design: This study is a single centre, single (assessor) blinded, and randomised controlled 
trial in patients with burns donor sites to their thigh. Patients will be randomly allocated into an 
experimental group (with pressure to donor sites) and a control group (with no pressure to donor 
sites), as the comparative treatment.  Groups will be compared at baseline according to the important 
prognostic indicators – age, donor site location, depth, size, and time since graft. The IPGT will be 
administered post-operatively (between day three to five depending on wound review and dressing 
changes). Patients will continue to wear the IPGT 23 hours per day for a period of 8 weeks, and will 
be given two pairs of pressure pants at a time. Participants will be asked to complete a log of wear 
time / use documenting how long that the IPGT is worn each day. This will enable one pair to worn, 
while the other is in the wash. Washing instructions will be provided. Follow up assessments and 
garment replacement will be undertaken fortnightly for a period of 2 months. 
 
Discussion: This study focuses on a unique area of burns scar management using a low pressure 
tubular support garment (IPGT) for the reduction of donor site scar because such therapy, 
specifically for donor scar management is poorly represented in the literature. This study was 
designed to test a cost effective scar prevention treatment for patients with donor sites to the thigh.  
No known studies of this nature have been carried out to date, and there is a need for rigorous 
clinical evidence for low pressure support garments for donor site scar minimisation. 
 
Trial Registration: ACTRN12610000127000. Registration date 08/02/2010 
https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=335119 
Protocol Date and Version Number:  15/03/2010 - Version 1.3 
Key Words: Interim Pressure Garment, Donor Site, Burns, Occupational Therapy 
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4.1 Introduction 
Red thickened scars can reduce physical function and create a distorted physical appearance for a 
burn-injured patient (Wisley et al, 2010; Druery et al, 2005; Brown et al, 2008). When a burn 
penetrates deeply enough into the dermis of the skin, surgery is often required to assist healing.  The 
surgery involves removing the burned or dead skin (debriding) and replacing it with a thin section of 
unburned healthy skin (donor skin), known as a Split Thickness Skin Graft (STSG).  This donor skin 
is surgically removed, commonly from the patient’s own thigh area, using a Dermatome at a measure 
of 8:1000 inch to 12:1000 inch (depending on the thickness required to heal the burn defect) and 
includes the epidermis and the upper third of the dermis (Singer & Clark 1999; Muller et al, 2007). 
The tissue removed for a STSG is comparable in depth to a partial thickness skin loss (Muller et al, 
2007). The remaining exposed area of dermis is referred to as the donor site. The donor skin is then 
placed over the original debrided burn wound area to assist in healing. There are sufficient residual 
epidermal cells in the remaining dermis of the donor wound to allow re-epithelisation to occur over 
an approximate 14 day period (Singer & Clark, 1999). The donor site wounds discussed in this paper 
are routinely dressed with ALGISITE, ACTICOAT, MELOLIN, and HYPAFIX (all from Smith & 
Nephew, Andover, MA, USA) and heavy crepe bandage immediately postoperatively until wound 
review day 3 or 5. After this time, the donor site is then dressed with soft white paraffin (Kenkay 
Pharmaceuticals, Smeaton Grange, NSW, Australia), Xeroform (DeRoyal, Powell, TN, USA), and 
HYPAFIX or heavy crepe bandage until the wound is considered healed (no raw, open or oozing 
epithelium). 
 
Despite the donor site depth being extremely thin, patients often describe this new wound to be like 
‘bad gravel rash’, and report worse pain in this wound than the original burn or graft site.  Pain 
associated with burn surgery has been shown to delay the patients return to work and daily functional 
activity, with donor sites consistently identified as a potential source of concern for burn patients 
(Wisley et al, 2010; Druery et al, 2005; Brown et al, 2008; Quinn et al, 2010; Demirtas et al, 2006; 
Anzarut et al, 2009). Protection and support of the remaining epidermal and dermal elements of this 
surgical wound (donor site) is recommended to assist effective tissue healing with minimal scarring 
(Muller et al, 2007; Ripper et al, 2009; Clark et al, 1996; Bloemen et al, 2009; Gurtner, 2007). 
 
A review of the literature published over the past decade identifies a number of treatments for scar 
minimisation including topical wound dressings, silicone gel sheeting, and pressure garment therapy 
(PGT) (Costa et al, 1999; Gibran et al, 2007). PGT has been used frequently since the early 1970’s 
to aid the healing of burns scars and graft sites by applying pressure to the scar (Ripper et al, 2009; 
Bloemen et al, 2009; Macintyre, 2006., Anzarut et al, 2009; Chang et al, 1995; Gladfelter, 2007; 
Watkins, 2010).  
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Whilst the optimal amount of pressure required for effective burn scar management is yet to be 
established (Atiyeh et al, 2013), the ranges reported as ‘effective’ in the literature vary from as low 
as 5mmHg up to 30 mmHg (Stella, Castagnoli, & Gangemi, 2008; Li-Tsang et al, 2015; Engrav et al, 
2010) with pressures above 30 to 40mmHg identified as being potentially harmful due to discomfort 
and paraesthesia (Stella et al, 2008; Macintyre, 2006; Chang et al, 2008; Candy et al, 2010). Despite 
these reported differences, PGT appears to enhance the scar maturation process following wound 
healing and, if worn for a minimum of 20 - 23 hours per day, also appears to inhibit the development 
of hypertrophic or abnormal scar tissue (Atiyeh et al, 2013; Li Tsang et al, 2015). The mechanical 
force applied by the garment is thought to restrict blood flow to the surface of the scar and reorganise 
collagen fibres to resemble that of normal skin (Ripper et al, 2009; Clark et al, 1999).  PGT has been 
reported at level 1 and 2 evidence as an effective treatment for hypertrophic burns scars (Anzarut et 
al, 2009; Candy et al, 2010; Engrav et al, 2010). 
 
PGT are applied as soon as possible after the burn wound has healed, and worn until the burn scar 
has matured or become pale in colour, resembling normal skin.  This process of scar maturation is 
reported to take 18 to 24 months, but can take longer in some cases (Quinn et al, 2010; Demirtas et 
al, 2010; Bloemen et al, 2009; Chang et al, 1995; Watkins, 2010; Engrav, Garner, & Tredget, 2007). 
While PGT is a well-known and well-utilised treatment by clinicians and an accepted intervention for 
scar reduction following a burn or graft, (Quinn et al, 2010; Demirtas et al, 2006; Ripper et al, 2009; 
Macintyre, 2006; Anzarut et al, 2009; Chang et al, 1995; Gladfelter, 2007; Watkins, 2010; Engrav et 
al, 2010; Partsch & Mosti, 2008; Partsch, 2005a) the effectiveness of pressure garments has not 
been scientifically assessed on donor site wounds.  Donor site wounds involve partial thickness skin 
loss and are comparable in depth to second degree burns which are frequently treated with PGT for 
scar minimisation. Therefore, the application of PGT for donor site scar minimisation is presumed 
beneficial based on this existing evidence. 
 
4.2 Pressure for donor support  
Occupational Therapists at the PSPABC and Specialist Outpatient Services – Burns Clinic in 
Australia currently utilise a low pressure (4-6 mmHg) interim garment on superficial/partial thickness 
donor site wounds. As these wounds should spontaneously heal within a 14 day period (Muller et al, 
2007), the medium to high pressures needed to have an effect on hypertrophic scars of deeper burn 
wounds may not be warranted. Rather, a gentler “interim” garment (termed Interim Pressure 
Garment Therapy, IPGT for the purpose of this study) is applied during the first few days post 
operatively for wound support. These interim garments are made from a tubular elastic material 
(similar in style to Lycra® cycling pants), and apply a gentle supportive pressure over the thigh and 
donor site areas.  
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Figure 4.1 shows a healed donor scar located                  Figure 4.2. The garment was extended to  
on the anterior thigh, that had application of IPG              support the hyper-vascular distal donor.  
and the hyper-vascular distal donor that did not. 
 
The use of IPGT in the treatment of burn donor sites at this centre has involved inconsistent 
application with a focus on wound dressing rather than scar management. Furthermore, the amount 
of pressure that the garments applied (4 – 6 mmHg) was previously undefined. The current evidence 
to suggest that IPGT may improve scar outcomes in donor sites is therefore anecdotal and 
observational. However, pressures as low as 5-15 mmHg have also been reported as having a 
benefit on scar minimisation (Van den Kerckhove et al, 2005; Atiyeh et al, 2002; Engrav et al, 2010; 
Li Tsang et al, 2005).  
 
4.3 Primary Objective 
The objectives of this research study are to establish evidence for tissue support (4-6 mmHg) in 
healing burn donor sites and to test the use of interim garments made from tubular support bandages 
for donor site scar management.  The specific objectives are to investigate whether low pressure 
IPGT support to donor sites results in: 
• Reduction of time to epithelisation  
• Reduction of erythema  
• Reduction of scar thickness/height  
• Improvement of overall scar appearance  
• Reduction of self-reported pain levels  
 
4.4 Methods 
4.4.1 Protocol and Registration 
This trial has approval from the Royal Brisbane and Women’s Hospital Human Research Ethics 
Committee (Approval No: HREC/09/QRBW/327), and from the University of Queensland Medical 
Research Ethics Committee (Approval No: MREC2010000356). The methodology has been 
documented in a protocol and registered on a publicly available site; (Australian New Zealand 
Clinical Trials Registry Number (ACTRN):12610000127000). The methods are summarised here 
according to the revised Consolidated Standards for Reporting Trials (CONSORT) statement 
(Kenneth et al, 2010; Schultz, Altman, & Moher, 2010).  
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Any amendments to the protocol will be submitted to the above research committees via written 
communique and approval sought. Once approval is received the relevant trial registries and journals 
will be updated accordingly. 
 
4.4.2 Design  
The clinical trial has been designed as a single centre prospective single blinded randomised 
controlled trial.   
 
4.4.3 Randomisation 
The Principal Investigator will consent and recruit the participants. Randomisation will be achieved 
through computerised tabulation with concealed allocation to each participant via a sealed envelope 
method. The implementation of this will be undertaken by a University of Queensland statistical 
analyst who is independent of the study. Participants will be randomly allocated into two groups, an 
experimental group of burn patients who will be provided with pressure to donor sites, and a control 
group of burn patients who will have no pressure to donor sites (the standard existing treatment). 
The research assistant responsible for taking Dermascan – C ® and POSAS measurements will be 
blinded to the treatment. This will be achieved through the removal of the participant’s garments by 
the Principal Investigator prior to the Research assistant entering the assessment room. 
 
4.4.4 Eligibility & Recruitment 
All new patients admitted to the Professor Pegg Adult Burns Centre who require split skin graft 
surgery for burn management < 10%TBSA will be screened for their eligibility to participate in the 
study by the principal investigator. Eligibility inclusion criteria include no burns to either thigh, right 
or left, donor site located on one thigh only (measured to be 10cm above the patella), male or female, 
14 years and over (with adult consent), and able to provide informed consent. Eligibility exclusion 
criteria include burns to left, right or both thighs, donor site on anatomical location other than the 
thigh, a psychiatric history documented in the medical chart which could cause a variable outcome 
(self-harm), a pre-existing co-morbidity associated with delayed healing, arterial disease / vascular 
compromise as documented in the medical chart, a dermatological condition in the region where the 
donor site needs to be harvested, allergy to ultrasound gel or no consent given. If eligibility is 
established, patients will be approached by the principal investigator and a lay explanation of the 
study procedure/requirements will be provided. Participants will be recruited once informed consent 
has been obtained and documented. Child assent will be documented where appropriate.  
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Figure 4.3 Participant flow diagram of the trial 
 
4.4.5 Intervention 
The treatment, IPGT will be administered post-operatively between days three to five. Patients in the 
treatment group will be required to wear the IPGT for 23 hours per day for a period of eight weeks.  
Participants in both groups will be reviewed every two weeks over the two month period to check 
scar and/or IPGT qualities (mmHg). Participants will be asked to complete a log of wear time / use 
documenting how long that the IPGT is worn each day. Donor site scar characteristics (e.g. pain, 
pliability) will be measured qualitatively using the Patient Observer Scar Assessment Scale with scar 
epithelisation and thickness will then be objectively measured using the Dermascan C ®.  Erythema 
and melanin will then be assessed using the DSM II ColorMeter  and groups will be compared at 
baseline according to the important prognostic indications – age, donor site location, depth, size, 
skin type and time since graft. Medical treatment (meaning surgical intervention, wound care 
dressings, medicines and nursing management) of the wound/burn/graft/donor or reconstructed area 
will be identical regardless of the group assigned, with the sole difference being that one group will 
have pressure therapy for their donor site, and the other will not.  
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The Principal Investigator will record demographics including age, skin type (as assessed using 
Fitzpatrick Skin Typing) (Fitzpatrick, 1988), cause of injury, percentage body surface area burned, 
depth of injury, surgical procedure undertaken, medications used and time taken to heal (including 
types of dressings used). A second researcher who is blind to the treatment will assess the height, 
thickness, pliability, colour and overall appearance of the scar, and the participant will also be asked 
to complete the patients section of the POSAS in relation to pain, itch and overall perceived 
appearance (Draaijers et al, 2004b; van der Wal et al, 2012).   
 
Following this, the ultrasound measurements will be carried out by a second researcher who is blind 
to the treatment using the Dermascan C ® Ultra-sound. Erythema and melanin will be assessed 
using the DSM II ColorMeter (Cortex Technology, Denmark) after which, the wound will be dressed 
by nursing staff as in a standard clinic. For participants in the non IPGT group the procedure is 
complete.  For participants in the IPGT group, the principal researcher will measure the amount of 
pressure in each garment and issue new interim garments if needed, thereby ensuring pressure 
remains constant. This concludes the assessment/treatment regime.  The participant will undergo 
the same regime at each subsequent appointment until they are suitable for discharge from the burns 
service.  At this point they will be released from the study. 
 
4.4.6 Standardization 
Considerations to standardise each measurement will include: 
• Measurement of the donor site with the garment removed for five minutes prior to assessment 
• Temperature controlled room 
• Position of donor site anatomically – dermatome location L3 – L5 antero-lateral thigh 
• A template on the donor site to identify the area to be measured 
• Investigator access and reliability 
• Time of day measured 
 
4.4.7 Outcome Measurement Tools 
The following are the commercially available and evidenced measurement tools utilised in this study: 
 
Time to Epithelisation and Scar Depth Assessment 
• The Dermascan – C® (Cortex Technology, Hadsund, Denmark) is a high frequency, high 
resolution ultrasound scanner which enables a non-invasive assessment of the skin to objectively 
capture and reproduce skin thickness. It can clearly discriminate between Hypertrophic Scar (HSc), 
normal scar and normal skin, and is evidenced as having high inter-rater/intra-rater reliability 
(Nedelec, 2008; Van den Kerckhove,2005) This process is recommended to objectively demonstrate 
time to wound closure or epithelisation (Gibran, 2013). 
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Erythema Assessment 
• The DSM II ColorMeter (Cortex Technology, Hadsund, Denmark) is a self-contained and 
battery operated device which provides objective measurements of erythema and melanin based on 
the light absorption characteristics of human skin (Nedelec et al, 2008a; Nedelec et al, 2008b; Van 
den Kerckhove et al, 2003; Draaijers et al, 2004a; van der Wal, 2013). 
 
Garment Pressure Assessment in mmHg 
• The PicoPress® Pressure Sensor (TT Medii Trade, Soleddet 15, DK 4180 Soro) has been 
clinically tested for validity and reproducibility in objectively measuring the pressure in mmHg of 
pressure garments.  It has been shown to be an adequate and reliable instrument for use in clinical 
trials that examine the pressure exerted by pressure garments (Partsch & Mosti, 2008; Mosti & 
Rossari, 2008). 
 
Subjective scar assessment 
• The Patient Observer Scar Assessment Scale (POSAS) has been shown to consistently 
demonstrate valid and reliable measures of scar qualities (van Zuijlen, Angeles, Kreis, Bos, & 
Middelkoop, 2002; Durani, McGrowther, & Ferguson, 2009; Draaijers et al, 2004b; Tyack, Wasiak, 
Spinks, Kimble & Simons, 2013; van der Wal et al, 2012). The study by van der Wal, (2012) provides 
valuable information regarding the psychometric properties of the POSAS using The Rasch analysis 
model (Van der Wal et al, 2012). Furthermore, the POSAS is one of two recommended scar scales 
suitable to detect change within subjects measured over time (Tyack et al, 2013). It is a simple and 
cost effective assessment that reports the patient’s opinions of the scar, including pain, itch, colour, 
stiffness, thickness, irregularity and overall appearance, and the observer assessment of 
pigmentation, thickness, relief, pliability, surface area, height, vascularity and overall appearance of 
the scar (Draaijers et al, 2004b; van der Wal et al, 2012, Simons et al, 2014; Tyack et al, 2013). 
 
Health Related Quality of Life (HRQoL) 
• This study will focus on the scar component of HRQoL outcomes. It is not anticipated that 
this study will impact on the broader outcomes of HRQoL at this stage. Reduction in pain will be 
recorded using the POSAS with smoking status, and employment status included in the initial 
interview participant data sheet.   
 
4.4.8 Sample Size  
Previous studies using the Dermascan C® have shown an effect size of 2.35 (1.69, 3.01) between 
skin thickness measurements of normal scar and normal skin (Van den Kerckhove et al, 2005).  For 
a minimum clinical difference of 0.5mm between groups of an alpha of <0.05 and a power of 0.9, 22 
subjects per group would be required (Van den Kerckhove et al, 2005; Lenth, 2006) (assuming a 
Standard Deviation of 0.5 mm for wound thickness).  
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Based on data from January 2013 to May 2015 (where patients admitted to the RBWH Professor 
Stuart Pegg Adult Burns Centre are represented as males = 593 admission and females = 237 
admission), the ratio is expected to be 3:1. This ratio should accurately reflect the distribution of 
burns within the general community. Additionally, during this time period, the average number of 
admissions for patients requiring SSG per year was 233. It is anticipated this will allow for sufficient 
recruitment (n= 44) to occur from a single site within a 12 month time period.  
 
4.4.9 Proposed Data Analysis  
Data will be entered into SPSS 23.0 for Windows (SPSS Inc, Chicago, IL) and tested for normality 
of distribution.  Descriptive statistics for all variables will be computed.  If parametric statistics are 
able to be used, a two way ANOVA for group*time will compare skin thickness between normal, 
donor and scar sites with a planned LSD post hoc analysis.  Significance will be set at p<0.05. If raw 
data is not normally distributed, an equivalent non parametric analysis will be used (Lenth, 2006).  
 
The project requires access to Confidential Information held by Queensland Health (e.g. 
demographic data in the medical chart). A Public Health Act – Application will be submitted to the 
data custodian (Director of Health Information Royal Brisbane and Women’s Hospital). The principal 
investigator will obtain and store data in a strictly confidential manner.  All participants will be treated 
fairly in accordance within the NHMRC guidelines for Research.  Research results and methods will 
be open to scrutiny by peers within the RBHW and, through publication at completion of the study, 
by the profession at large.   
 
4.4.10 Publication and dissemination 
The final results of the project will be disseminated through scientific avenues including presentations 
at relevant conferences and submission of manuscripts for journal publication in relevant peer 
reviewed journals. A report on the outcomes of this study will be submitted to the RBWH Trauma 
and Research Centre (Burns Trauma and Critical Care Research Centre), and other involved 
hospital committees, groups, and networks as required on completion of the study. 
 
4.4.11 Safety 
This study will not require a dedicated Data Safety Monitoring Board (DSMB) as IPG are used in 
current practice to hold dressings in place in the PSPABC. However, as these garments have not 
been used clinically for scar minimisation, an additional Risk Assessment for the use of these 
garments for this research has been completed in accordance with the Therapeutic Good 
Administration (Appendix B). Any adverse or unforeseen events will be reported as per standard 
RBWH procedure and will also be reported to the appropriate committee for review (RBWH 
HREC/UQ MREC). 
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4.5 Discussion 
Donor sites, regardless of their size, are consistently recognised as a potential source of concern. 
Cost effective interventions that accelerate healing and reduce scar formation would considerably 
improve postoperative management of wounds, such as donor sites (Gibran et al, 2007). This study 
aims to test the effects of IPGT (4 – 6 mmHg) for donor site support and scar healing, which is 
currently poorly represented in the literature.  
 
4.6 Conclusion 
If IPGT is shown to improve donor site scar maturation and healing, it is anticipated this outcome 
may assist in improving patient comfort, reduce the incidence of abnormal scarring and reduce the 
associated psychological stress of this additional wound (Costa et al, 1999). The potential benefits 
of establishing whether IPGT is effective in improving donor scarring may by reduce donor pain, itch 
and consequently length of stay (LOS), allowing people to return to work and resuming a normal 
lifestyle sooner. Furthermore, such an outcome may allow the healed donor site to be re-harvested 
more quickly for STSG for burn patients with large TBSA burns and limited donor site availability. If 
IPGT (4 – 6 mmHg) is shown to make no difference to donor scar healing, this outcome may result 
in savings to the overall health expenditure associated with burn care per patient. The outcome of 
the planned RCT will provide valuable information with regards the future of burns scar management. 
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CHAPTER 5:  
PILOT STUDY AND RESULTS 
 
The pilot study presented below was undertaken to test the logistics of the study protocol outlined in 
Chapter Four. As a pilot, the following study sought to improve the quality and efficiency of data 
collection, and to identify deficiencies in the design of the proposed research. It also sought to obtain 
preliminary evidence of the effectiveness of Interim Pressure Garment Therapy (3 – 6 mmHg) on 
surgical donor wounds to guide the design of a larger RCT. 
 
The effect of Interim Pressure Garment Therapy on donor site healing in burns patients: a pilot 
study for a randomised controlled trial. 
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Abstract: This pilot investigation of eight participants is a precursor to the planned clinical trial (n = 
44). The objectives of the pilot are threefold; firstly, to test the feasibility of the planned research 
outlined in the study protocol; secondly, to improve the quality and efficiency of data collection, and 
identify deficiencies in the study design; and thirdly, to obtain preliminary evidence of the 
effectiveness of Interim Pressure Garment Therapy (3 – 6 mmHg) on surgical donor wounds of burns 
patients who have sustained less than 10 % TBSA. This information will be used to inform correct 
sample size for future studies. This information will be used to guide the design of a larger RCT in 
the future. 
 
Methods: This study was a single centre, single (assessor) blinded, randomised, controlled trial in 
patients post burn injury with donor sites taken from the thigh.  Patients were randomly allocated into 
an experimental group with IPGT and a control group without IPGT.  Groups were compared at 
baseline for important prognostic indicators – age, burn depth, donor size, time since donor site 
acquisition, co-morbidities, smoking status, alcohol intake, and medications. The IPGT was 
administered post-operatively (between day three to five depending on wound review and dressing 
changes). Patients continued to wear the IPGT 23 hours per day for a period of 12 weeks, and were 
given two pairs of pressure pants at a time. This enabled one pair to worn, while the other was in the 
wash. Washing instructions were provided. Follow up assessments and garment replacement were 
undertaken fortnightly for a period of 3 months. 
 
Results: The primary objectives of this study were met, in that the feasibility of the study design was 
determined, and the preliminary findings regarding the effectiveness of IPGT were obtained. The 
results indicated a trend towards a decrease in donor site scar thickness over time for the IPGT 
group, compared to the control group. The secondary objective was also met, and recommendations 
for the use of the ultrasound machine were identified. 
 
Conclusion: The application of low pressure IPGTs is a feasible, safe and practical scar 
management technique for donor sites. Further studies are required to determine the effectiveness 
of this intervention.  
 
Trial Registration: ACTRN12610000127000. 
Key Words: Interim Pressure Garment, Tissue Support, Donor Sites, Burns, Occupational Therapy 
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5.1 Introduction 
The management of superficial donor site wounds aims to maximise wound healing and prevent 
hypertrophic scar development. The effectiveness of topical donor site wound treatments, such as 
dressings to promote wound healing has received attention over the last few years with a number of 
randomised controlled trials completed or underway (McBride et al, 2015; Bollero et al, 2010; 
Schintler, 2012; Demirtas et al, 2010; Markl et al, 2010; Geary et al, 2012; Lyall & Sinclaire, 2000). 
However, evidence of the effectiveness of pressure garment therapy for wound healing or scar 
management of superficial donor site wounds appears to be lacking (Singer & Clark 1999; Muller et 
al, 2007; Ripper et al, 2009; Clark et al, 1996; Bloemen et al, 2009; Gurtner, 2007).  
 
Superficial wounds should heal without scarring if they heal spontaneously within a 10 to 14 day 
period (Shupp et al, 2010), and standard donor wounds harvested at a depth of 8 to 10:1000 inch 
(Muller et al, 2007) should technically be no exception. However, superficial donor site wounds are 
often more painful than the recipient site (Birchall, 1991) and are at risk of hypertrophic scarring 
(Batkin et al, 2013).  Pain associated with burn surgery, and itch associated with wound healing 
(Carrougher et al, 2013) have been shown to delay the patients return to work and to reduce daily 
functional activity (Wisley et al, 2010; Druery et al, 2005; Brown et al, 2008; Quinn et al, 2010; 
Demirtas et al, 2010; Anzarut et al, 2009). Furthermore, donor site scars can remain erythematous 
and cosmetically may not resemble normal skin for up to 12 months post-surgery (Nedelec, 2014). 
Therefore, research that investigates the effectiveness and feasibility of pressure garment therapy 
as a potential treatment for donor site healing and scar management is needed. 
 
5.1.2 Donor site support using dressings 
A review of the literature published over the past decade reflects advances that have been made in 
understanding the process of wound healing and scar formation (Costa, et al, 1999; Gibran et al, 
2007). Tissue support of donor wounds is essential to maximise healing, and there are numerous 
papers documenting the benefits and limitations of different donor healing methods including 
dressings such as hydrocolloids, silver impregnated, impregnated gauze, alginates, and negative 
topical pressure therapy such as Vacuum Assisted Closure (VAC) dressings (Bollero et al, 2010; 
Schintler, 2012; Demirtas et al, 2010; Markl et al, 2010). Despite this, there is no apparent ‘gold 
standard’ dressing for donor sites (Geary et al, 2012; Lyall & Sinclaire, 2000).  
 
McBride et al (2015) identify possible reasons for this:  
1. treatment is concentrated on the grafted site with the donor site a second priority; and,  
2. despite knowledge that a moist healing environment promotes epidermal regrowth, evidence 
surrounding dressing preference for donor wounds is lacking.  
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While dressings are integral to donor wound recovery, other factors to facilitate scar maturity include 
treatment methods that reduce skin tension (Widgerow et al, 2000). This reduction in skin tension 
may be one of the actions of IPGT. 
 
5.1.3 Donor site support using pressure 
In the early stages of wound healing, a scar is unstable and immature (Fujimori et al, 1968). A factor 
causing abnormal scar development is tension on the newly forming matrix. To stabilize this tension 
the scar requires support (Widgerow et al, 2000).  Continuous external pressure applied to surgical 
wounds with paper tape has been shown to prevent early scar hypertrophy through the reduction of 
skin tension (Atkinson et al, 2005). However, to our knowledge there is no existing study that 
explores the effectiveness of low level external mechanical pressure in the form of IPGT to hasten 
donor site healing and reduce the formation of abnormal scarring. 
 
5.2 Objectives 
The objectives of the pilot are threefold; firstly, to test the logistics of the planned research outlined 
in the study protocol; secondly, to improve the quality and efficiency of data collection, and identify 
deficiencies in the study design; and thirdly, to test the hypothesis that Interim Pressure Garment 
Therapy (3 – 6 mmHg) will improve surgical donor wounds of burns patients who have sustained 
less than 10 % TBSA. This information will be used to inform correct sample size for future studies. 
 
5.3 Methods 
5.3.1 Protocol and Registration 
This trial was approved by the Royal Brisbane and Women’s Hospital Human Research Ethics 
Committee (Approval No: HREC/09/QRBW/327), and from the University of Queensland Medical 
Research Ethics Committee (Approval No: MREC2010000356).  The methodology has been 
documented in a protocol and registered on a publicly available site - the Australian New Zealand 
Clinical Trials Registry Number (ACTRN):12610000127000.  The methods are summarised here 
according to the revised Consolidated Standards for Reporting Trials (CONSORT) statement 
(Kenneth et al, 2010).  
 
5.3.2 Design  
The clinical trial was designed as a single centre prospective single blinded randomised controlled 
trial.  The interview and testing time points were planned at fortnightly intervals for a period of two 
months from time of donor site acquisition.   
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5.3.3 Randomisation 
Randomisation was achieved through computerised tablature with concealed allocation to each 
participant via a sealed envelope method.  Participants were randomly allocated into two groups, an 
experimental group who were provided with pressure to donor sites and a control group who had no 
pressure to donor sites (standard treatment). 
 
5.3.4 Eligibility 
All patients admitted to the Professor Stuart Pegg Adult Burns Centre requiring split skin graft surgery 
for burn management of less than 10%TBSA were screened for their eligibility to participate in the 
study by the principal investigator.  Eligibility inclusion criteria included a donor site on one thigh only 
(measured to be at least 10cm above the patella), no burns to either thigh (right or left), male or 
female, aged 14 years or older (with adult consent), and the ability to provide informed consent.  
Eligibility exclusion criteria included a donor site on an anatomical location other than the thigh; burns 
to either thigh (left or right); a psychiatric history documented in the medical chart which could cause 
a variable outcome (self-harm); a pre-existing co-morbidity associated with delayed healing; arterial 
disease/vascular compromise as documented in the medical chart; a dermatological condition in the 
region where the donor site was taken; allergy to ultrasound gel; or no consent given.  Once eligibility 
was established, patients were approached by the principal investigator and an explanation of the 
study procedure/requirements was provided.  Participants were included once informed consent was 
obtained and documented.  
 
5.3.5 Intervention 
The treatment IPGT was administered post-operatively between day three to eight and objectively 
measured in millimetres of mercury (mmHg) using the PicoPress® Pressure Sensor (Mosti & 
Rossari, 2008; Partsch & Mosti, 2010).  Participants in the treatment group were asked to wear the 
IPGT for 23 hours per day for a period of eight weeks.  Both groups were reviewed every two weeks 
over the two month period to check scar and/or IPGT pressures (mmHg).  Surgical intervention, 
wound care dressings, medication, nutrition, exercise and nursing management (of the 
wound/burn/graft/donor or reconstructed area) were consistent between groups, with the sole 
difference being that one group had IPGT for their donor site, and the other did not. 
 
Demographics were recorded by the principal investigator including age, skin type (as assessed 
using Fitzpatrick Skin Typing) (Fitzpatrick, 1988), cause of injury, percentage body surface area 
burned, depth of injury, surgical procedure undertaken, medications used, smoking status and time 
taken to heal (including types of dressings used). A second researcher who was blind to the 
treatment assessed the height, thickness, pliability, colour and overall appearance of the scar.  
Participants were asked to complete the patient section of the POSAS. Adherence to IPGT was 
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measured by asking the participant to complete a self-report questionnaire regarding how many 
hours per week and per day the IPGT was worn.   
 
Imaging of the scar was undertaken using echo-graphic evaluation using a high frequency ultrasound 
at 50mHtz high resolution. B-mode was used to obtain a two dimensional image of the scar. The 
mean scar depth was established between the skin surface and the inner limit of the dermis (the 
hypo-echogenic subcutaneous fat). The ultrasound velocity used to determine skin thickness was 
1580m/s, with the viewing length of field limited to 6mm and a skin depth penetration of 3 mm 
(Dermascan C® Ultrasound, Cortex Technology Denmark). Aqueous gel was applied to the 
donor/probe interface during recording of the image. The ultrasound measurements were carried out 
by a second researcher who was blind to the treatment using the Dermascan C® ultrasound. 
Measurements were taken of the donor site in addition to a section of normal skin for comparison on 
the contralateral thigh. The minimum and maximum scar thickness points on the donor site image 
were recorded, in addition to the average scar thickness at each time point for both groups.  
 
Following the ultrasound measurement, the wound was then dressed by nursing staff as per 
standard clinic practices. For participants in the IPGT group, the principal researcher then measured 
the amount of pressure in each garment and issued new IPGTs if the pressure recorded fell below 
4mmHg, to ensure the pressure remained constant. At each time point, the amount of pressure 
measured at the IPGT-scar interface was recorded with data obtained for the fitting pressure of the 
new IPGT (FP), current pressure following wearing (CP), pressure loss over time (PL). 
 
Participants underwent the same procedure at each subsequent appointment until two months post 
donor site formation or until they were discharged from the burns service if the latter occurred prior 
to 2-months post-donor site formation.   
 
5.3.6 Measurement Tools 
The measurement tools utilised in this study have been outlined in the previously documented Study 
Protocol (Chapter Four), thus they will not be outlined in detail in this chapter.  The Dermascan – C 
(Cortex Technology, Hadsund, Denmark) was used to measure scar thickness (Nedelec, 2008; Van 
den Kerckhove, 2003). The DSM II ColorMeter (Cortex Technology, Hadsund, Denmark) was used 
to measure erythema (van der Wal et al, 2013). The PicoPress® Pressure Sensor (TT Medii Trade, 
Soleddet 15, DK 4180 Soro) (Mosti & Rossario, 2008; Partsch & Mosti, 2010) was used to measure 
pressure beneath pressure garments. The Patient Observer Scar Assessment Scale (POSAS) was 
used to measure the patient self-report of the scar symptoms of itch and pain, the physical properties 
of the scar and the perceived overall appearance of the scar.  
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The observer component of this assessment was used to assess the vascularity, pigmentation, 
thickness, relief (topography of the scar), pliability and surface area, as well as the overall 
appearance of the donor site (Draaijers et al, 2004). These tools are commercially available, well 
validated, and previously reported in Chapter Four of this thesis. The control group did not have 
IPGT, therefore this group did not have pressure readings recorded. All other outcomes measures 
were the same for the intervention group.  
 
5.3.7 Sample Size 
Previous studies using the Dermascan C have shown an effect size of 2.35 (1.69, 3.01) between 
skin thickness measurements of normal scar (donor sites) and hypertrophic scar (Van den 
Kerckhove et al, 2003; Nedelec et al, 2008a; Nedelec et al, 2008b).  For a minimum clinical difference 
of 0.5mm between groups, a p<0.05 and a power of 0.9, 22 subjects per group were required 
(assuming a standard deviation of 0.5 mm for wound thickness) (Lenth, 2006; Van den Kerckhove 
et al, 2003). Based on data from January 2013 to May 2015 (where patients admitted to the RBWH 
Professor Stuart Pegg Adult Burns Centre were represented as male = 593 admissions and females 
= 237 admissions) the ratio of males to female participants was expected to be 3:1.  This ratio 
accurately reflected the distribution of burns within the general community. 
 
5.3.8 Statistical Analysis  
Data will be entered into SPSS 22.0 for Windows (SPSS Inc, Chicago, IL).    Descriptive statistics 
such as the mean and standard deviation were computed for all variables.  The outcome measures 
were tested for normality and were found to have a normal distribution therefore parametric statistics 
were used (Lenth, 2006). A repeated measure between/within ANOVA a time by group interaction 
compared scar thickness between control and intervention groups at various time points.  An LSD 
post hoc analysis was conducted to adjust for multiple comparisons.  Significance was set at p<0.05.  
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5.4 Results 
The average days post-burn at recruitment was 14 for the control group (SD = 18.16) and 17 for 
the intervention group (SD = 18.81). Demographic information was the only data collected at 
recruitment.  All participants were categorised according to Fitzpatrick’s Skin Type I – VI 
(Fitzpatrick, 1988). The majority of skin types were III - IV (75%). The mean days post donor 
harvest at baseline data collection was 3.75 (SD1.5) for the intervention and 4.5 (SD2.38) for the 
control group. The days post donor site harvest for the follow-up time points are listed in Table 5.1. 
The predicted time points for follow up reviews that were planned at fortnightly intervals for a 
period of three months following baseline were not achieved for reasons that included participant 
dropout, failure to attend an appointment, patient rescheduling and scheduling errors by clinic 
administration staff.  
 
Table 5.1 Mean (SD) interview time points in days post-burn 
 
The demographics of the participants and the characteristics of the donor sites are reported in 
Table 5.2. Participants were 5 males (62.5%), and 3 females (37.5%) aged 19 to 63 years. The 
mean age of participants was 41.5 years (SD = 15.26) for the control group and 43.0 years (SD = 
19.09) for the intervention group. The control group donor sites were larger than the intervention 
group; with a mean of 15.37cm (SD 6.94) by 12.62cm (SD 5.85) for the control group and 16.0 cm 
(SD 5.58) by 7.37cm (SD 2.68) for the intervention group. This group difference may have 
impacted on healing times in that the smaller wounds of the intervention group may have healed 
faster and therefore biased the results.  
 
There was also a difference in the prevalence of smoking between the groups.  Twenty-five 
percent of the control group were smokers compared to fifty percent of the intervention group. The 
nicotine inhaled from smoking reduces nutritional blood flow to the skin as a result of 
vasoconstriction, which can result in tissue ischemia and impaired wound healing (Silverstein, 
1992).    
 
Interview time 
points 
  
 
Days post  
donor harvest 
to time point 1 
baseline 
Means (SD) 
 
 
Days post  
donor harvest 
to time point 2 
 
Means (SD) 
 
Days post  
donor harvest 
to time point 3 
 
Means (SD) 
 
Days post  
donor harvest 
time point 4 
 
Means (SD) 
     
Intervention 
 
3.75 (1.5) 15.75 (9.7) 26.0 (5.0) 60.0 (22.60) 
     
Control 
 
4.5 (2.38) 16.75 (2.87) 42.25 (16.52) 55.33 (9.07) 
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Table 5.2 Participant demographics  
 
 
Demographics 
 
All participants 
n = 8 (100%) 
Mean  (SD)* 
 
Non – IPGT 
n = 4 (50%) 
Mean  (SD)* 
 
IPGT  
n = 4 (50%) 
Mean  (SD)* 
    
Age at injury (years) 42.25 (16.02) 41.5  (15.26) 43  (19.09) 
BMI 26.76  (5.12) 29.33  (5.67) 24.19   (3.38) 
TBSA <10% 1.75 (1) 2.0 (1.08) 1.5 (1) 
Time since burn (days) at recruitment 15.50 (17.19) 14.0 (18.16) 17.00 (18.81) 
Time since graft (days) at baseline 4.12 (1.88) 4.5 (2.38) 3.75 (1.50) 
Dermatome depth (1000th inch) 9.25:1000 (1.03) 10:1000 (0) 8.5:1000 (1.0) 
Donor height from mid patella (cm) 24.50 (8.22) 25.25 (2.8) 23.75 (12.17) 
Donor width (cm) 10  (5.06) 12.625  (5.85) 7.375 (2.68) 
Donor length (cm) 15.68  (5.84) 15.37 (6.94) 16 (5.58) 
Smoking status (n, %) 37.5*  25* 50* 
Cigarettes (number p/day)  4.375  (6.23) 3.75   (7.5) 5 (5.77) 
Fitzpatrick’s Skin Phototype (n, %) 
                              II* *  
                              III** 
                              IV** 
 
25 
37.5 
37.5 
 
0 
50 
50 
 
25 
50 
25 
* except where indicated 
**I = pale white skin, II = white skin, III = light brown skin, IV = moderate brown skin, V = brown skin, VI = 
deeply pigmented skin. Types I and II are not provided as no participants had that skin type. 
 
All donor sites were dressed with the same layered combination of dressings. This being ALGISITE, 
ACTICOAT, MELOLIN, and, HYPAFIX (all from Smith & Nephew Andover, MA, USA), and then 
changed at the second time point of 15.75 days (SD 9.7) for the intervention group and 16.75 days 
(SD 2.87) for the control group to soft white paraffin (Kenkay Pharmaceuticals, Smeaton Grange, 
NSW, Australia), Xeroform (DeRoyal, Powell, TN, USA), and HYPAFIX or heavy crepe bandage until 
the wound was considered healed (no raw, open or oozing epithelium). No participants in either 
group required dressings after the third time point.  
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The pressure loss over time for each garment in the IPGT intervention group was assessed and 
recorded. Table 5.3 demonstrates a 1mmHg loss over time at each interview. Participants reported 
wearing their IPGTs a mean of 20.25 (SD 5.5) hours up to the second time point; 16 (SD 6.92) hours 
a day seven days a week up to the third time point; and 12 (SD 6.92) hours a day 7 days a week up 
to the fourth time point.  
 
Table 5.3 IPGT pressures including mmHg loss over time and patient adherence  
 
 
 
Time Points 
 
 
IPGT Participant 
 
A B C D 
     
Time point 1 (baseline)     
             FP* (mmHg) 3 4 5 5 
     
Time point 2     
CP 2 3 4 4 
PL 1 1 1 1 
Days worn (hrs) 7 7 7 7 
Hours/day worn (hrs) 23 12 23 23 
FP 4 4 5 5 
     
Time point 3     
CP 3 3 - 4 
PL  1 1 - 1 
Days worn (hrs) 7 7 - 7 
Hours/day worn (hrs) 20 8 - 20 
FP 4 4 - 5 
     
Time point 4     
CP 3 3 - 4 
PL  1 1 - 1 
Days worn (hrs) 7 7 - 7 
Hours/day worn (hrs) 20 8 - 8 
      
Abbreviations: CP = current pressure, PL = pressure loss, FP = fitting pressure 
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For the POSAS Observer Scale parameters (Table 5.4) there was no significant effect over time for 
pigmentation, relief (scar topography), or scar surface area. There was a significant effect over time 
for vascularity (p=0.02), thickness (p=0.007), pliability (p=0.005) and overall scar appearance 
(p=0.002). There was no significant effect for the time by group interaction for vascularity, 
pigmentation, relief, pliability, thickness, scar surface area or the overall scar appearance.   
 
Table 5.4 POSAS Observer Scale means, standard deviations and significance by group 
and time by group. 
Parameter Group Baseline 2 3 4 Significance 
       
Vascularity Control 4.33 (1.53)  3.33 (0.56)  3.0 (0.56) 2.67(0.058) Time #p=0.02 
Time*Group NS 
p=0.46 
 Intervention 4.0 (1.0) 2.67 (0.58) 3.67 (0.58) 2.0 (0.52)  
Pigmentation Control 3.0 (0.41) 2.3 (0.58) 2.0 (0.40) 2.33 (0.58) Time NS p=0.31 
Time*Group NS 
p=0.59 
 Intervention 2.67(0.58) 3.0 (1.0) 2.33 (0.58) 2.33 (0.52) 
Thickness Control 2.0 (0.41) 2.33 (0.56) 1.0 (0.0) 1.67 (0.58) Time #p=0.007 
Time*Group NS 
p=0.14 
 Intervention 2.33 (0.57) 1.67 (0.58) 1.33 (0.58) 1.0(0.0) 
Relief  Control 2.33 (0.58) 2.33 (0.58) 1.67(0.58) 1.33 (0.58) Time NS p=0.11 
Time*Group NS 
p=0.87 
 Intervention 2.0 (1.0) 1.67 (0.58) 1.67(0.58) 1.0 (0.00) 
Pliability Control 2.33 (0.58) 2.0 (0.0) 1.0 (0.0) 1.0 (0.0) Time #p=0.005 
Time*Group NS 
p=0.68 
 Intervention 2.33 (0.58) 2.0 (0.00) 1.3(0.58) 1.0 (0.0) 
Surface area Control 1.0 (0.0) 1.0 (0.0) 1.0 (0.0) 1.0 (0.0 Time NS  
p value N/A 
Time*Group NS  
 Intervention 1.0 (0.0) 1.0 (0.0 1.0 (0.0) 1.0 (0.0) 
Overall scar 
appearance 
Control 
Intervention 
4.0 (0.0)  
4.0 (1.0) 
3.33 (0.58) 
3.33 (0.58) 
3.0 (0.0)  
3.0 (0.0) 
2.67 (0.58)  
2.0 (0.0) 
Time # p=0.002 
Time*Group NS 
p=0.59 
Note: Time*Group = time by group interaction; # = significant p value 
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For the POSAS Patient Scale parameters (Table 5.5) there was a significant change over time for 
pain (p=0.04), colour (p=0.002) and stiffness (p=0.01). There was a trend towards a significant 
change over time for thickness (p=0.07) and the overall scar appearance (p=0.08).  There was a 
trend towards a significant effect for time by group interaction for thickness (p=0.08). There was no 
significant effect for a time by group interaction for pain, itch, colour, stiffness, irregularity and overall 
appearance.  
 
Table 5.5 POSAS Patient Scale means and standard deviations and significance by group and 
time by group 
Parameter 
 
Group Baseline Time 2 Time 3 Time 4 Significance 
  
 
     
Pain 
 
Control 5.67 (4.16) 2.0 (1.0) 1.33 (0.58)  1.33 (0.58) 
 
Time # p=0.04 
 
Time*Group NS 
p=0.48 
 
 
Intervention 3.0(2.0) 1.0 (0.0) 1.0 (1.0) 1.0 (0.0) 
Itch 
 
Control 2.33 (2.31) 6.33 (3.22) 3.67 (2.52) 1.33 (0.58) Time NS p=0.14 
 
Time*Group NS 
p=0.29  
 
Intervention 2.67 (2.08) 2.33 (1.53) 2.0 (1.0) 1.3 (30.58) 
Colour 
 
Control 10.0 (0.0) 8.67 (1.16) 8.33 (1.53) 5.67(2.08) Time p=0.002 
 
Time*Group NS 
p=0.34  
 
Intervention 8.0 (2.65) 8.67(1.53) 5.33 (3.22) 4.67(1.53) 
Stiffness 
 
Control 7.33 (4.62) 2.67 (1.53) 1.67(1.16) 3.0 (2.0) Time # p=0.01 
 
Time*Group NS 
p=0.14  
 
Intervention 2.67 (2.08) 1.33(0.58) 1.67(0.58) 1.33 (0.58) 
Thickness 
 
Control 3.0 (1.73) 5 (2.65) 1.67(1.16) 1.33 (0.58) Time NS p=0.07 
 
Time*Group NS 
p=0.08  
 
Intervention 2.0 (2.1) 1.33 (0.58) 1.33 (0.58) 1.33 (0.58) 
 Irregularity 
 
Control 4.67 (3.51) 5.67(0.58) 3.0 (1.0) 2.0 (1.0) Time NS p=0.29 
 
Time*Group NS 
p=0.39  
 
Intervention 4.33(4.93) 1.33 (0.55) 1.67(0.58) 1.67(0.58) 
Overall Scar  
 
Appearance 
 
Control 
 
Intervention 
8.33 (2.89)  
 
7.0 (5.20) 
8.33 (1.53) 
 
2.33 (1.53) 
5.67 (2.08) 
 
2.0 (1.0) 
4.67 (4.73) 
 
3.33 (1.53) 
Time NS p=0.08 
 
Time*Group NS 
p=0.38 
Note: # = significant difference over time; NS = not significant; Time*Group = time by group interaction  
 
For the Dermascan C® parameters (Table 5.6) there was a significant effect over time for minimum 
scar thickness (p = 0.007), maximum scar thickness (p = 0.005) and mean scar thickness (p = 0.014). 
There was a significant effect for the time by group interaction for the normal skin comparison  
(p = 0.04).  
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For the DSM II Colorimeter parameters there was no significant effect for either time or the time by 
group interaction, for colour and melanin.  
 
Table 5.6 Dermascan-C ® and DSM II ColorMeter means, standard deviations and significance by 
time and time by group  
Parameter Group Baseline 2 3 4 Significance 
Dermascan C       
Thinnest scar 
(mm) 
Control 0.552 (0.08) 0.67(0.13) 0.90 (0.19) 1.13 (0.42) Time 
#p=0.007 
Time*Group 
NS p=0.59 
 Intervention 4.6 (0.06) 0.63 (0.18)  0.76 (0.29) 0.80 (0.24) 
Thickest scar  
(mm) 
Control 0.82 (0.11) 0.98 (0.23) 1.27 (0.16) 1.63 (0.24) Time 
#p=0.005 
Time*Group 
NS p=0.38 
 Intervention 0.68 (0.22) 0.93 (0.32) 0.82 (0.35) 1.14 (0.39) 
Average scar 
depth (mm) 
Control 0.80 (0.17) 1.02 (0.20) 1.68 (0.35) 1.62 (0.09) Time 
#p=0.014 
Time*Group 
NS p=0.56 
 Intervention 0.60 (0.18) 0.75 (0.1) 1.00 (0.32) 1.49 (0.09 
Normal skin 
comparison 
Control 0.91 (0.10) 0.83 (0.12) 0.73 (0.03) 0.74 (0.18) Time NS 
p=0.56 
Time*Group 
^p=0.04 
 Intervention 0.63 (0.12) 0.91(0.25) 0.97(0.42) 1.12 (0.30) 
 
DSM II 
ColorMeter 
      
Colour Control 24.67 (2.05) 20.35 (5.90) 23.60 (6.53) 21.83 (5.67) Time NS 
p=0.38 
Time*Group 
NS p=0.82 
 Intervention 27.14 (4.68) 20.89 (4.87) 23.08 (2.52) 19.65 (3.19) 
Melanin Control 38.27 (5.71) 34.19 (6.44) 40.19 (3.90) 43.57 (8.23) Time  NS 
p=0.42 
Time*Group 
NS p=0.44 
 Intervention 37.48 (5.91) 41.23 (4.69) 43,83 (3.38) 41.85 (5.48) 
Note: # = significant difference over time; ^ = significant difference between groups over time; 
Time*Group = time by group interaction 
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As one of the aims of this pilot study was to inform future studies as to required sample size, 
calculations were undertaken using a planned alpha of 0.05, a power of 0.8 and the variability and 
difference in means obtained in this data set.  
The web site for sample size calculation 
(http://hedwig.mgh.harvard.edu/sample_size/js/js_parallel_quant.html) was utilized.  
 
Table 5.7 shows the calculation of the projected sample size for each parameter based on the 
variability achieved in this study. As can be seen some parameters require very large amounts of 
subjects and therefore data collection in these areas may not be feasible. The parameters of patient-
reported pain, stiffness, thickness and observer parameters of pigmentation, relief, pliability and 
surface area all required large participant numbers of greater than 1,000 which is usually not feasible 
in a single centre study. 
 
Table 5.7 projected sample size for POSAS parameters 
Parameter Calculation of 
Sample  
Size per group 
Parameter Calculation of 
Sample  
Size per group 
    
Patient  Observer  
Pain >1000         Vascularity       94 
Itch       80         Pigmentation  >1000 
Colour       14         Thickness        14 
Stiffness >1000         Relief  >1000 
Thickness >1000         Pliability  >1000 
Irregularity       14         Surface  >1000 
Overall   1000         Overall       26 
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Figure 5.1 CONSORT 2010 Flow Diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.5 DISCUSSION 
The results of this IPGT pilot study indicated a trend towards a decrease in donor site scar thickness 
over time for the IPGT group, compared to the control group. This is the only finding that 
demonstrated a potential difference between the groups out of all the parameters tested in this pilot 
study.  This finding is important as the formation of thickened scars has been documented as one of 
the most important long term morbidities following burn injuries (Nedelec et al, 2014) with thickened 
scarring documented as being unsightly, painful and impacting on daily function (Wisley et al, 2010; 
Druery et al, 2000; Brown et al, 2008; Quinn et al, 2010; Demirtas et al, 2006; Anzarut et al, 2009; 
Nedelec et al, 2014). Burns donor site wounds are no exception, as each time the skin integrity is 
interrupted, an opportunity is created for abnormal scarring to occur (Sharp et al, 2015). 
Assessed for eligibility (n= 23) 
Excluded  (n= 15  ) 
   Not meeting inclusion criteria (n= 5 
>10% TBSA ) 
   Declined to participate (n= 0  ) 
   Other reasons (n= 10 ) 
Analysed (n= 3) 
Over an 8 week period rather than 12 weeks 
due to the attrition rate of the control group 
Discontinued intervention (no longer felt they 
needed treatment) (n= 1) 
  
Allocated to intervention (n= 4) 
 Received allocated intervention (n= 4 ) 
 
Lost to follow-up (no fixed address) (n=1) 
Discontinued intervention (DNA at the final 
time point) (n= 2) 
Allocated to control (n= 4) 
 Received standard care (n= 4) 
 
Analysed (n= 4) 
Over an 8 week period rather than 12 weeks 
due to the attrition rate of this group 
 
 
 
Allocation 
Analysis 
Follow-Up 
Randomized (n= 8) 
Enrollment 
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The finding of a trend towards a decrease in scar thickness for the IPGT group compared to the 
control group corresponds to the findings of a systematic review of the effectiveness of pressure 
garments on burn scarring that found scar thickness was the only scar parameter to demonstrate a 
small but significant difference between pressure garment intervention and control groups using 
meta-analyses of the results of randomised controlled trials (Anzarut et al, 2009). With this in mind, 
as thickness was the only parameter that demonstrated a trend towards a significant group effect 
over time it should be the focus of future planned RCTs. 
 
The results of this pilot study also indicated that there were a number of parameters such as pain 
and itch severity that appeared to reduce over time.  These findings correspond to longitudinal 
studies of burn scars (Li-Tsang et al, 2015; Carrougher et al, 2013; Stella et al, 2008). However, 
evidence of the effect of IPGT on itch and pain remains anecdotal as no differences between the 
groups over time were found possibly due  to such low participant numbers therefore further testing 
with a larger number of participants is required to establish the effectiveness of IPGT for reducing 
itch and pain.  
 
As anecdotal evidence suggests itch is an important parameter to monitor in people with donor site 
wounds this parameter should continue to be included in future trials.  Further, evidence is available 
to support the effectiveness of pressure garments that provide a minimum of 5 to 15mmHg in patients 
with scarring caused by burns; to reduce symptoms such as itch, as well as scar pain and overall 
clinical appearance of the scar (Cheng et al, 1984; Li-Tsang et al., 2015). However, the application 
of these findings to participant groups such as those in this study needs to be confirmed as the 
Chinese cohorts included are at higher risk of hypertrophy than Caucasian cohorts (Li-Tsang, 2015) 
and thus may have more severe symptoms than a Caucasian cohort.  Further, the study of Li Tsang 
et al (2015) only had six participants with a total of ten scar sites all of whom were from the Chinese 
population thus studies with greater numbers of participants are required for confidence in the 
findings.  
 
Recruitment for this pilot occurred over a three month period and in this time only eight participants 
were able to be included. One participant in the experimental group was lost to follow up at week 
four, and one participant from the control group was lost to follow up at week six, with a further two 
withdrawing at week 12. Only four participants completed the study to week 12. Of the three 
participants left in the experimental group, adherence to wearing IPGT varied from 20 hours a day 
for the first 10 weeks and dropped dramatically to 12 hrs a day during the last fortnight of the study. 
Reasons reported by participants for no longer wearing garments were heat interfering with sleeping 
at night or scarring no longer being a concern. The rate of dropout in this study corresponds to those 
of Holavanahalli et al (2006) who described participation rates at 6, 12, and 24 months follow-up 
time points as reducing over time from 64%, to 54%, and 42% respectively.  
 s33634065  56 | P a g e  
 
With this in mind, large numbers of participants are required to account for attrition rates 
(Holavanahalli et al, 2006)such as those found in this study.  
 
For the planned RCT the smallest sample size estimate was 14 for colour and thickness.  As only 
eight participants were able to be recruited for this pilot study, the study was underpowered to detect 
significant difference between the groups over time.  Similarly, to be adequately powered for the itch 
parameters, the pilot study required 80 participants per group to detect significant differences 
between the groups. Thus it was not surprising that for itch no significant group differences were 
found between the groups over time.  Based on the pilot data obtained the sample size will be 
reviewed prior to commencing a full RCT. The previous effect size was based on the best available 
data, but that was not a best match for the two groups in the proposed study. 
 
A further limitation of this study was the variation in the length of time between data collection time 
points for each participant. It was anticipated that data points would be no more than two weeks 
apart to allow for the IPGT to be replaced frequently. However, participants did not return as 
frequently as planned and therefore the follow-up time points were not the same for all participants. 
This may have impacted on the results and should be accounted for in future studies.  Choosing a 
statistical analysis such as mixed effects regression would account for the variation between follow-
up time points and should be considered in future trials to permit patients to be followed up when 
they attend clinic appointments rather than having to come back at set follow-up points. 
   
It was expected that replacement of the garments at the fortnightly time point would maintain a 
constant low pressure to the donor site and also prevent pressure loss over time. Despite the fact 
that low pressure garments have been shown to lose less pressure over time than high pressure 
garments (Van den Kerkove et al, 2005), it was thought that the IPGT pressure may be lost after two 
weeks of wash/wear as lower pressures were found for these garments compared to the pressures 
beneath other garments documented in the literature. However varied time points over the 3 month 
period demonstrates only a 1 mmHg loss.  
 
The authors acknowledge that there are many factors that have the potential to impact upon wound 
healing for donor sites; location of donor, depth of donor, severity of burn wound and TBSA, infection, 
dressings, nutrition, patient demographics / compliance, comorbidities, and pharmacologic 
requirements that should be controlled for in future clinical trials. 
 
Finally the clinical utility of the Dermascan C® was not acceptable and therefore the usefulness, 
benefits, and drawbacks of the device are now discussed (Smart, 2006). During data collection it 
became apparent that the time taken to set up the Dermascan C® Ultrasound was inefficient in a 
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busy clinic. The ultrasound machine needs to be connected to wall socket power to run. There is no 
battery operated power to enable easy transportation between rooms.  
 
The device is cumbersome, with several pieces and is designed to be stationary. However, patients 
are standardly allocated to single rooms for treatment in the burn clinic, and therefore as data 
collection was running at a parallel with the clinic, researchers were required to follow each patient 
in their allocated room with the device. It took approximately 5 minutes to set up the Dermascan C® 
for initial data collection for each room change. To enable transportation of the device a large metal 
trolley was utilised, which consequently took up a large amount of space in each room (Figure 5.2 ). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 Demonstrates the size of the           Figure 5.3 shows the size of the probe 
Dermascan set up on a mobile trolley.              in the hand.  
 
The probe is large (15cm x 5cm x 8cm), heavy in the hand (800g) and awkward to hold and position 
on a fragile donor wound. It takes approximately 90 seconds to prepare each time an accurate 
measurement needs to be taken.  Preparing the probe for use involves the following steps; 1) 
emptying the water from the probe, 2) removing the lens cover and plastic wrap, 3) placing new 
plastic wrap smoothly onto the lens and clipping the lens cover on, 4) filling the syringe with sterile 
water and injecting it into the probe, 5) applying a thin film of ultrasound gel to the probe, and 6) 
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removing any excess gel without wrinkling the plastic wrap. It is important to ensure no air bubbles 
are present in the gel at the end of this process. Once the probe has been prepared several 
measurements can be taken in succession providing no wrinkling of plastic wrap occurs.  If contact 
with the patient’s skin is not adequately made then the ultrasound image is not clear.  However, it is 
this contact of the plastic wrap with the patient’s skin that can cause the wrinkling over repeated 
applications. This meant that the clinical meaningfulness of the data collected was compromised due 
to varying image quality (plastic wrap / artefact). Image quality improved with practice however image 
analysis in this setting was impractical and required additional time which was again not ideal for 
patients in a busy clinic. 
 
Prior to the commencement of this study a one day training session was available to the 
investigators, and while ongoing support was offered, it was via email only. This limited the ‘hands 
on’ education needed to develop experience with limited error. Additional software that would enable 
transfer of images to a standard computer for storage and analysis was not purchased at the time, 
due to financial constraints. This meant that all images had to be analysed as soon as possible 
following collection, then saved from a screen shot and pasted in to a word document for storage. 
Further analysis of the images was only possible on a paper copy, once they had been transferred 
from the Dermascan C® processing unit. Lastly, although the device was under warranty, technical 
support was not available in Australia when it ceased working. Rather, it was sent back to Denmark 
for repair and commencement of data collection was postponed for the ensuing three weeks. 
Fortunately, this did not occur during data collection, as time points for participant review in the 
research were important.  
 
There are a large number of recommendations identified in this study. Further consideration of these 
is discussed in Chapter 6 of this Thesis.  
 
5.5.1 Implications for practice and research 
Based on the numbers obtained in the IPGT pilot study over a three month period an adequately 
powered trial is likely to take two years or more years to obtain the required sample size.  Adequate 
funding to purchase and replace the low level pressure garments required in a larger trial is a further 
consideration.   A feasible alternative may be the choice of a longer lasting temporary garment (such 
as Skins ® Performax ®, 2XU ®), however pilot testing would need to be undertaken to ensure their 
sizing guide was accurate and that pressure loss was minimal and remained within standard range 
prior to inclusion in a future RCT.    
 
IPGT provides a means of protecting the donor site during wound healing and may assist to prevent 
or reduce scarring although evidence of their effectiveness for these purposes is limited. The term 
‘Interim’ represents a temporary support garment that can be worn in the initial stages of healing. 
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The rationale for using low pressure IPGT at the participating site as part of standard care was that 
during the early stages of re-epithelisation and cell migration, the donor wound may be too fragile to 
tolerate the high pressures (20 – 30mmHg) of a standard pressure garment.   
 
5.5.2 Future Directions  
The results established by this pilot indicate that the planned RCT should include scar thickness as 
a primary outcome and that further research regarding the use of IPGT would be a feasible adjunct 
treatment for burns donor sites in the absence of alternative tissue support. Continued data collection 
and commencement of the planned RCT for IPGT is required to demonstrate if low pressures (4 – 
6mmHg) may be effective to induce scar maturation for problematic donor sites.  Ethical clearance 
has been obtained for such an RCT to determine the effectiveness of IPGT on donor sites at the 
same hospital site as this pilot study. No known studies of this nature have been carried out in 
Australia to date.  There remains the need for rigorous clinical evidence for IPGT for donor site 
management. 
 
5.6 Conclusions 
The primary objectives of this pilot study were met, in that the feasibility of the study design was 
determined, and preliminary findings regarding the effectiveness of IPGT were obtained but need to 
be interpreted with caution. The results indicate a trend towards a decrease in donor site scar 
thickness over time for the IPGT group, compared to the control group. Additionally, an estimation 
of numbers required for a definitive RCT was completed.  
 
The secondary objective of this pilot was also met, and recommendations for use of the ultrasound 
machine were identified. The outcome measures used were shown to be practical with reasonable 
completion rates at follow-up. However the Dermascan-C® was shown to be impractical for a busy 
outpatient clinic. The final Chapter (Six) will discuss the clinical utility of the Dermascan Ultrasound 
® and its application to a busy clinical environment for burns scar assessment in addition to future 
recommendations for further research in this area. The future directions and conclusions of the 
research follow and are discussed in Chapter Six. 
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CHAPTER 6:  
DISCUSSION AND CONCLUSION  
 
6.1 Overview 
The research presented in this thesis was designed to test a low pressure support garment as an 
adjunctive intervention for superficial donor site wounds in order to provide evidence for such an 
intervention, which up until now has been lacking.  The overall aim of this research was to introduce 
and explore the possibility of IPGT as a novel treatment for burns donor site support in the early 
stages of wound healing (less than three months post-harvest).  
 
There were six main aims which guided the research and these have been addressed in the following 
manner: 
 
1. A review of the literature has been conducted to discuss the theoretical basis and hypothesis 
for pressure therapy donor site wounds.  
 
2. The concept of low level pressure garment therapy (4 – 6 mmHg) for tissue support and scar 
minimisation of superficial donor wounds was introduced 
 
3. A study of 47 participants was undertaken to determine and standardise the pressure range 
(mmHg) applied to the thigh by IPGT.  
 
4. A study protocol was designed for a clinical trial that aims to test the effectiveness of IPGT 
for donor site scar minimisation.   
 
5. Based on the above protocol, a pilot study of eight participants was conducted to improve the 
quality and efficiency of data collection, and identify deficiencies in the design of the study 
protocol. 
 
6. Finally, two publications have been submitted for review to disseminate the theory of low 
pressure support for further discussion. 
 
 
This thesis explores the hypothesis that the application of a low superficial pressure applied 
externally to the donor wound (in the form of IPGT) may: mimic normal skin tension; prevent donor 
wound distension and subsequent micro-tears in the newly forming epidermis; and reduce the effects 
of the inflammatory response, which may give rise to a hypertrophic scar response in the later stages 
of the healing process 
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Objective measurement of the varied parameters in this study appears to support the hypothesis 
that IPGTs may be beneficial for donor wounds in the following ways; 
 
Firstly, in the absence of the superficial layers of skin (that have been removed by donor site 
harvesting), IPGT may provide low pressure tissue support that mimics normal skin tension. This 
may assist to reduce wound distension that can occur when gravity is increased, such as when the 
patient stands to mobilise. Wound distension may compromise the fragile tissue integrity of this 
newly created wound. Secondly, the low pressure applied by IPGT may provide support to normalise 
interstitial tissue pressures in the newly healing donor wound. This may assist to stabilise the 
chemical and mechanical signals that react to increased interstitial wound tension and consequently 
cause thickened scarring, such as TGF-β. Finally, IPGT may also assist to minimise scarring through 
the protection of tissue integrity that can be compromised by friction caused when dressings move 
against the skin. 
 
The overall results from the investigation into IPGT for donor support are limited. However, the 
investigation has enabled a review of the findings to guide and improve the future direction of 
research in this area. These are now raised. 
 
6.2 Results 
The study presented in Chapter Three demonstrated that: 
1. The interface pressure between the thigh and the IPGT that was previously unknown was 
found to be 3 – 5.8 mmHg at the thigh garment interface. 
2. This pressure was low compared to pressures documented from custom-made pressure 
garments. 
3. A standard pressure range (mmHg) was obtained beneath the IPGT applied to the thigh for 
donor healing using a sizing method we developed based on thigh circumference.   
This information will be used in future clinical trials of the effectiveness of these garments to minimise 
scarring and improve wound healing.  
 
Overall the results of the pilot study presented in Chapter 5 indicate that:  
1. IPGT as a treatment for donor site management was shown to be safe and tolerated. 
2. Outcome measures were shown to be practical with good follow up and completion. 
3. There was a trend for IPGT for donor wound support to be effective in improving the thickness 
of donor scars.  
4. An estimation of numbers required for a definitive study have been identified. 
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During this study it became apparent that the Dermascan-C® was impractical for a busy outpatient 
clinic. The impact of the clinical utility of this device will be discussed later in this chapter.  
 
6.3 Discussion  
Donor sites share many characteristics of wound healing associated with partial thickness burns, 
such as increased risk of pain, infection, abnormal scar formation and itch (Gibran et al, 2007; 
Carrougher et al, 2013; Nedelec et al, 2014). All donor sites have been identified as being at risk of 
scarring (Batkin et al, 2013) and furthermore donor scars do not resemble normal skin for at least 
12 months post-harvest (Nedelec et al, 2014). Evidence for the ideal management of the donor site 
wound and the associated symptoms of abnormal scarring, pain and itch remains inconclusive with 
little consensus on what is the ideal treatment to promote healing and minimise scarring (Demirtas 
et al, 2010; Markl et al, 2010; Atiyeh et al, 2000; Läuchli et al, 2013; McBride et al, 2014).  
 
Tubular support bandages off the roll are commonly applied to hold dressings in place across most 
Australian burns units. They are utilised for the early management of burn scars and acute oedema 
management (personal communique). Clinical judgement of the appropriate size of tubular 
bandages off the roll is made by clinical experience more often than not, and furthermore it is not 
part of routine clinical practice to measure the pressure beneath the tubular support bandages once 
prescribed.  
 
The mechanisms of external pressure on hypertrophic scar prevention and remodelling has been a 
topic of discussion for over 40 years (Larson & Futtrup, 1971., Fujimori et al, 1968; Deitch et al, 1983; 
Rose et al 1985; Judge et al, 1984; Nedelec, 2014; Van den Kerckove, 2007; Tredget, 1999; Cheng 
et al, 1984). At a cellular level however, the histological role of key factors including myofibroblasts 
and keratinocytes, in addition to the timing of events such as apoptosis can be complex for clinicians 
to interpret and apply in the clinical environment.  
 
In addition to this, scarring of superficial wounds is not well evidenced due to the spontaneous nature 
of these wounds to heal within 7 to 14 days and therefore heal without scar (Shupp et al, 2010). 
Donor sites are documented to have sufficient residual dermal components to regenerate the 
excised superficial layers (Demirtas et al., 2009, Atiyeh et al, 2002). However, donor wounds are 
presented in the literature to be at risk of hypertrophy (Batkin et al, 2013), with reasons including 
varying time to healing due to depth of procurement, pressure exerted by the surgeons hand when 
harvesting may cause the wound to be deeper than anticipated, infection, wound management and 
patient factors such as the individual immune response (Lee et al, 2012 in Hernodon (ED Total Burn 
Care). 
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As discussed in detail previously, the disruption of the integrity of skin during STSG harvesting can 
result in a new painful wound for the patient, which is often reported as worse than the original burn 
injury or newly grafted site (Demirtas et al, 2010). Therefore protection of the remaining epidermal 
and dermal elements of the donor site are essential criteria for effective wound healing with minimal 
scarring (Singer & Clark, 1999; Muller et al, 2007; Ripper et al, 2009; Clark et al, 1996; Bloemen et 
al, 2009; Gurtner, 2007). The strengths and limitations of the research into IPGT as a treatment 
option to fulfil these criteria are now presented.   
 
6.4 Strengths and limitations 
The main strengths of this thesis are the new research findings from the studies undertaken. The 
limitations of the research are also discussed. 
 
6.4.1 Study One. The sizing study reported in chapter two is the first study to determine the amount 
of pressure, and variability of pressure at the thigh garment interface, provided by IPGT fabricated 
from tubular support bandages. The results indicated firstly, that the pressure applied in mmHg at 
the IPGT/thigh donor site interface immediately after the first application, was low (3 to 5.8 mmHg) 
when compared to prior studies reporting pressures beneath medium to high pressure garments 
used for hypertrophic scar management. Secondly, that there was minimal variability in the 
pressures recorded, a standardised sizing method was able to be established. Limitations of study 
one include that participants did not have donor site wounds or scars and all pressures recorded 
were all obtained as static readings, therefore cannot be generalised to the pressures obtained 
during dynamic movement. Clinical judgement of the appropriate size of tubular bandages off the 
roll is made by clinical experience more often than not, and furthermore it is not part of routine clinical 
practice to measure the pressure beneath the tubular support bandages once prescribed. Currently 
in Australia this study presents the first known evidence for measuring pressure applied by custom 
made IPGT (fabricated from tubular support bandages) at the thigh to burns donor sites. 
 
6.4.2 Study Two. The pilot patient study reported in chapter four is one of two known studies that 
utilised the Dermascan C® ultrasound to assess wound thickness specifically on burns donor sites 
(Nedelec et al, 2015). The Dermascan – C® (Cortex Technology, Hadsund, Denmark) is a high 
frequency, high resolution ultrasound scanner which objectively captures and reproduces skin 
thickness.  It is clinically appropriate and has been shown to clearly discriminate between 
Hypertrophic scar (HSc), normal scar and normal skin and has been utilised as an objective 
assessment tool in scar research (Nedelec et al, 2008; Van den Kerckhove et al, 2005; Fearmonti, 
2010).  
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Two probes are available; a 20 MHz, 1580m/s, 60 - 200 µm low resolution probe that provides depth 
of 10 – 15 mm penetration (Figure 6.1); and a 50mHtz high resolution, 1580m/s, 30 - 60µm probe at 
a depth of 3 mm, with a viewing length of 6mm.  Both probes provide a cross sectional image of the 
epidermis, and the dermal collagen fibre matrix. The high resolution 50mHtz probe was used for the 
IGPT and donor site research covered in this thesis, and an example of captured images are shown 
in figure 6.2.  
 
 
Figure 6.1 Example of skin layers using a 20 MHz probe (Cortex Technology Denmark) 
 
 
Day 6 Absent epithelium                    Day 10 Epithelium regenerating       Day 21 Intact epithelium 
Figure 6.2 example of Dermascan C ® images using 50 MHz probe 
 
The device consists of a transducer, an amplification system, and a data storing system with 
ultrasound images saved and processed with specific image analysis software (Dermavision, Cortex 
Technology., Seidenari et al, 1994) as shown in figure 6.3. 
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Figure 6.3 Dermascan C® Hardware (Cortex Technology) 
 
In the previous chapter, the pilot study identified several potential difficulties with the use of the 
Dermascan C® in a busy clinical environment.  
 
The final major limitations of this study include the low subject numbers (n = eight), the attrition rate 
and the reliance on patient honesty regarding IPGT adherence. Sharp et al (2015) state that the 
successful implementation of a pressure therapy protocol involves patient compliance or adherence 
and list the following as reasons: Skin irritation, heat, discomfort, length of treatment, associated 
cost, and loss of pressure in the garment, patient perception, self-esteem, and social interactions 
(Sharp et al, 2015). Furthermore, the distance and travel time that is required of a patient to return 
for review can also have impact on attrition rate (Atkinson et al, 2005).  Recommendations for 
improvement of these factors include the use of outcome photos of scars treated with and without 
pressure, educational handouts describing the principles behind pressure therapy and the expected 
outcomes to improve participant understanding and therefore compliance, and finally to improve 
psychosocial adjustment, facilitate self-management and individualise treatment through means 
such as garment colour choice (Sharp et al, 2015).  
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6.5 Future Directions 
Tubigrip off the roll is commonly used in Australian burn centres as a first line treatment for oedema 
management, to keep dressings in place or as an interim measure until the high pressure (20 – 
30mmHg) custom garments can be tolerated. Anecdotally, evidence suggests the application of 
tubular bandages in the form of IPGT could also be beneficial in improving the overall appearance 
of donor sites. This thesis has explored low level pressure therapy (4 – 6 mmHg) for donor site tissue 
support and scar minimisation during healing. It is the first known study that specifically focuses on 
mechanical support for burn donor sites and therefore it would be beneficial to continue to investigate 
the effects of low level pressure therapy on superficial donor wounds.  
 
Since the commencement of this study, more ergonomically sound scar assessment equipment has 
become available. Cortex Technology, the manufacturer of the Dermascn C ® have released a 
portable laptop version (Dermascan C USB) with built in software that can store up to 100 images at 
a time and enables easy transfer into word or other documents on a connected PC. However, to 
maximise the effectiveness of the current Dermascan C ®, the experience of a trained sonographer 
may improve the quality of the output. Additional software is available for purchase which would 
enable images to be downloaded and reviewed on a standard computer. This would improve 
analysis time. Furthermore, the environment in which the data were  collected could be improved. It 
is recommended that the Dermascan - C ® be used in a single temperature controlled room, with 
individual appointments made for measuring and follow up. During data collection in a busy clinic 
environment, the benefits of a separate room would eliminate the need to transport the cumbersome 
ultrasound machine and reconnect to power each time. This portability would additionally prevent 
loss of time when booting the machine between each room change. Other benefits to an allocated 
data collection room would include less interruption from nursing, medical and other allied health 
staff attempting treatment during the same time. The author believes this would improve the data 
collection process for both patients and investigators. 
 
Continuation of research in this area requires increased participant numbers to yield statistically 
significant results. The sample size calculation prior to commencement of the research suggested a 
minimum of 44 subjects (22 per group) would be required to achieve a significant result however, 
experience suggests that a larger number would be required to account for attrition and compliance. 
Where possible, recruiting participants that lived within close proximity to the hospital has been 
shown to improve attendance at ongoing reviews (Atkinson et al, 2005) and therefore improve the 
quality of data collection.  
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6.6 Conclusion 
This research has focused on a unique area of burns donor site scar management however, it is 
acknowledged that the use of pressure garment therapy is only one component for donor site 
management. The overarching aim of the research undertaken was to test a low pressure tubular 
support garment (IPGT) as a potential intervention to firstly, support the healing of donor wounds of 
burn patients, and secondly, to improve the overall appearance of the donor site scar. The 
completion of both studies discussed in Chapter Three and Chapter Five of this thesis has enabled 
rigorous planning for an RCT to further test this theory. No known studies of this nature have been 
carried out to date, and there is a need for rigorous clinical evidence for these garments for donor 
site support and scar minimisation.  
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APPENDIX B: Supporting Documentation 
 
Appendix B 1 Risk Assessment: Essential Principles for Medical Devices 
Australian Medical Devices Guidance Document Number 22 - TGA 
 
This document addresses the Assessment of Risk for the use of Tubigrip in the manufacture of 
Elasticised Bike Pants within the Occupational Therapy Department of the Royal Brisbane and 
Women’s Hospital. 
 
TRADENAME  TUBIGRIP  
Elasticised Tubular Bandage - Cotton Elastin 
FABRIC MANUFACTURER Molnlycke Health Care AB,  
Box 13080 SE - 402 52 Goteborg, Sweden.  
www.molnlycke.com 
FABRIC DISTRIBUTOR Clifford Hallam HealthCare  
 
Intended Purpose of Tubigrip 
The registration for Tubigrip on the ‘Australian Register for Therapeutic Goods’ (ARTG) states the 
intended purpose of the product as; 
 “Tubigrip Elasticated Tubular Bandage” – Manufacturer MOLNLYCKE  
“As a multi-purpose tubular bandage - Tubigrip provides tissue support in the treatment of strains and sprains, 
soft tissue injuries, joint effusions, general oedema, post- burn scarring and ribcage injuries and is also used 
for pressure dressings and arm fixation.” 
“Tubigrip is made from cotton with covered elastic threads laid into the fabric to form free-moving spirals. The 
fabric is available in two colours – natural shade and flesh shade.” 
“Tubigrip provides lasting, effective support with complete freedom of movement for the patient. Once the 
bandage has been applied, covered elastic threads within the fabric move to adjust to the contours of the body 
and distribute pressure evenly over the surface. Fitting is quick and easy. Tubigrip stays securely in position 
without pins or tapes, unlike conventional crepe bandages.”    MOLNLYCKE 
Under the TGA Certificate: ARTG Number 156209 (See attached Certificate and Public Summary) 
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Risk Assessment: 
Royal Brisbane and Women’s Hospital 
Essential Principles for Medical Devices 
Australian Medical Devices Guidance Document Number 22 - TGA 
 
PART 1: Addressing General Principles: Tubigrip / Elasticised Bike Pants 
This document demonstrates how Elasticised Bike Pants meet the criteria for demonstrating “no 
harm” according to the TGA risk assessment process. These garments are made from a cotton 
elastin material (Tubigrip) and are fabricated into the sized elastic bike pant garment. 
 
Essential Principle 1 – The use of Medical Devices not to compromise health and safety 
 
Elasticised (Tubigrip) Bike Pants are provided by Occupational Therapists at the Royal Brisbane 
and Women’s Hospital. The Occupational Therapist utilises their technical knowledge, and 
experience to prescribe the garments, and monitor their effect on the clinical management of burn 
donor sites. The fit of the Bike Pants is reviewed on a regular basis for each patient to ensure the 
Bike Pants do not compromise their health and safety.  
 
Written documentation, education and verbal explanation is provided to each patient who receives 
Bike Pants. This includes information regarding the wearing regimen, washing instructions and 
precautions for use. (See attached in Essential Principle 13.) 
The benefits and risks associated with their use are documented in Essential Principle 6. 
 
Essential Principle 2 - Design and construction of medical devices to conform to safety principles  
 
DESIGN and CONSTRUCTION: 
Elasticised (Tubigrip) Bike Pants are designed to be applied over the thigh and abdominal area.  
Patterns are used to ensure the same sizes are fabricated.  
The current dimensions for the cut of each pattern size are as follows; 
 
Size Waist  Mid Thigh  
Extra-Small 29cm 16cm 
Small 32cm 19cm 
Medium 38cm 20cm 
Large 41cm 22cm 
Extra-Large 44cm 23cm 
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x 
The Occupational Therapy Assistant (OTA) at the RBWH is provided with on site competency 
based training to ensure the consistent standard of production of bike pants. 
This training is provided and co-ordinated by the Senior OTA.  
Labelling of each sized bike pant is provided by; small / medium / large marked on the waist of 
each garment with permanent marking pen. 
The plastic package of each bike pant is labelled for size and date of production.  
 
Sewing Instructions  
Tubigrip Bike Pants  
- Small, Medium and Large Bike Pants are all made out of size “L” Tubigrip. 
- When manufacturing Bike Pants, all seams are worn on the outside of the pants, not the 
inside. This is to ensure that there is no pressure areas created when being worn. 
 
Method: 
Cut the Bike Pants with inner leg seam running side by side. 
This means reversing the back pattern piece on the fabric. 
1) Roll out Tubigrip and position pattern as below. 
 
 
 
 
 
 
 
 
 
2) Cut out pattern, including along fold (F). Mark pants with either F (front) or B (back). 
3) Overlock crotch seams together for both front and back 
 
 
 
 
 
 
4)  Join front and back sides by overlocking side seams together  
 
 
 
F F B B 
Fold 
F 
B 
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5)  Join front and back inside of legs together by overlocking the seams. It may be easier to pin 
the two sides together at the bottom of each leg and at the centre of the crutch; this will 
ensure that both side align correctly 
 
 
 
 
 
 
6) Overlock the top of the Bike Pants and the bottom of the legs to prevent the Tubigrip from 
fraying. When overlocking, make sure the material is stretched when it is sewn. This is to 
allow the material to stretch when it being put on by a patient. 
 
 
 
 
 
 
 
7) Fold over the top of the Bike Pants so that there is a +/- 2cm fold. Starting at the front of the 
Bike Pants, sew (zig zag) the fold down, leaving a 1cm gap at the front of the garment. 
Ensure that the material is stretched when sewing to allow the garment to be stretched 
when being worn.    
(Use slightly larger more open zigzag stitch). 
 
 
 
 
 
  OR   
 
 
 
 
 
Zig zag 
1cm gap 
Fold 
F 
A    
C B 
D at the back of the 
garment 
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8)  Attach +/- 1.5m of 1cm thick ribbon to a safety pin. Insert safety pin into fold of Bike Pants 
through 1cm gap. Thread ribbon through and tie at the front using a bow. 
 
9)  Package in a small plastic bag and label the size and month of manufacture. 
 
To open the crotch on the Bike Pants for hygiene purposes. 
 
All marks are made with a fine tip marker or pen. 
 
1. Lay the pre-made Bike Pants out on a flat surface. Front side on the top 
 
2. On the front of the Bike Pants mark on the seam approximately 3cm up (A) from the 
crotch joining seam.  And on the inner leg seam mark approximately 2cm from the 
very centre of the all crotch seams. On each side (B) and (C) 
 
3. On the back of the Bike Pants mark on the seam approximately 3cm up from the 
Crotch joining seam (D). 
 
4. Now with a fine marker, draw a curve from the top mark (A) to the centre marks (B) 
and (C) on each side. Extend this to (D).  This forms an oblong shape.  This is the 
line that you cut-out to create the “hole”. Approximately 8cm long by 2cm wide.  
(This hole becomes much larger once over-locked).  
 
5. Overlock the hole area to prevent fraying of the Tubigrip. 
 
6. If  a larger hole is required extend the position of the marks by 1.5cm on all 
Marking positions.    A,B,C,D. 
  RBWH OTA Manual of Procedures 2010 
 
Essential Principle 3 - Medical devices to be suitable for intended purpose  
 
**The intended purpose of the product remains the same as specified in the Manufacturers 
product statement listed on page 1 of this document. 
 
Elasticised (Tubigrip) Bike Pants are applied over the thigh and abdominal area, including any 
dressings that are positioned on the patient.  
 
The Bike Pants start at the waist and finish just above the knee.  
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They are worn the same way that a pair of sports bicycle pants are worn by cyclists.  
 
Elasticised (Tubigrip) Bike Pants provide a gentle compressive support to the thigh and abdominal 
area.  
 
Essential Principle 4 - Long term safety  
 
 
1. The fabric (Tubigrip) is used within the designated timeframe as printed on each box by the 
Manufacturer.  
2. The fabric is kept according to Manufactures instruction and utilised within the expiry date. 
3. The Elasticised Bike Pants (made from the Tubigrip Fabric) are replaced once the material 
starts to lose its elasticity. 
4. The clinical intent of the Tubigrip Fabric (as stated in Essential Principle 3) remains the 
same for the Elastic Bike Pants. 
5. The latency of the product is assessed by the clinician at the time of prescription. 
6. The shelf life of Tubigrip is stated as 4 years by the Manufacturer, within a stable 
temperature environment. 
 
Essential Principle 5 - Medical devices not to be adversely affected by transport or storage  
 
N/A.  The RBWH is not responsible for the transport or storage of this product. 
 
Essential Principle 6 - Benefits of medical devices to outweigh any side effects  
 
The benefits of reviewing and evaluating the use of Elasticised Bike Pants through a clinical trial 
include; 
 
1. Improved understanding of the effects of Pressure therapy on donor site healing. 
2. Increased knowledge of the efficacy and effectiveness of a cost effective intervention that may 
improve the postoperative management of donor sites. 
3. Improved capacity for return to Activities of Daily Living (ADL) or  work following burn injury. 
4. Further tailoring of treatment to determine patient comfort, cosmetic appearance of the scar, and 
potentially minimise donor scar formation in burns patients.  
5. Provide valuable information for the management of expanding budget requirements for 
Occupational Therapy in burns scar management.  
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PART 2 Principles about design and construction: Tubigrip / Elasticised Bike Pants 
 
Essential Principle 7 - Chemical, physical and biological properties  
Tubigrip is made from cotton with covered elastic threads laid into the fabric to form free-moving 
spirals.  
The fabric is available in two colours – natural shade and flesh shade. 
Once fabricated, the garment is worn inside out (i.e. with seams on the outside) to prevent 
pressure or irritation on fragile skin. 
Essential Principle 8 - Infection and microbial contamination 
 
Elasticised Bike Pants are manufactured, altered, provided, and utilised according to infection 
control policy and procedures of the RBWH as detailed below.  
 
 81012/ALL: Contact Precautions,  
 82610/ALL: Decontamination - Patient Care Equipment, 
 81003/ALL: Standard Precautions,  
 81300/ALL: Decontamination – Blood and Body Fluid Spills,  
 82600/ALL: Environmental Decontamination,  
 
http://hi.bns.health.qld.gov.au/rbh/policies/infec
tion_control.htm 
   
1. Infection Control Protocol for Sewing Machine Operation & Garment Manufacture  
This protocol aims to meet IFC requirement of a public hospital. The RBWH OT Department 
manufactures all garments. 
 
ENVIRONMENT: 
The sewing environment includes sewing machine and overlocker located in Occupational Therapy 
Department RBWH.  The sewing tables are to be left clear to enable wiping down of table surface. 
Other sewing equipment and supplies will be located close to but not in contact with the sewing 
machine and overlocker tables. Hand washing gel (micro-shield gel) will be located close to the 
sewing area.  In addition, a hand washing basin, paper towels and gloves are accessible in the 
room. 
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PROCEDURE:  
1.   New manufacture of interim Pressure garments: 
 
 Prior to use for new manufacture, the sewing tables and machines will be wiped down with 
a wet cloth and neutral detergent. 
 To clean inside the sewing mechanism, an alcohol wipe will be run through the sewing 
machine and overlocker for a single length of the cloth. 
 
2. Modification of garments for inpatients and outpatients who have a MRO. 
 
 Where patients have MRO, all garments requiring modification with the sewing machine 
and / or overlocker will require washing prior to sewing. 
 The washing process involves 
 Hand wash garment item in adequate amount of water for the garment in a bucket 
with neutral detergent. 
 Rinse garment item thoroughly in running tap water. 
 To dry garment quickly press between layers of a clean towel and place in spin 
cycle of washing machine and hang on drying rack with cold set fan blowing directly 
on garment. 
 The water temperature used should be lukewarm as hotter temperature will damage 
the garment. 
 Harsher detergents or bleaches are not to be used as these will damage the elastic 
fibres in the Pressure garments.  Specifically damage includes:- 
 Shrinking of garment 
 Decreasing longevity of garment 
 Damage to elastic fibres rendering Pressure as in-effective for prescribed 
need 
 Where a garment for a patient with MRO has been placed in the washing machine, 
an empty wash cycle with detergent set on hot water will be run prior to next 
washing machine use. 
 It is the primary responsibility of the Occupational Therapy Assistant (Burns) to wash 
garments for burns patients as above.  Where the OTA is away and no backup cover is 
available, Occupational Therapy staff can wash garments where required following the 
above procedure. 
 It is the responsibility of the treating Occupational Therapist to notify the OTA that the 
garment modification required is for a patient with MRO so that appropriate infection control 
protocol can be followed. 
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 It is the responsibility of the treating Occupational Therapist to advise the patient and others 
such as family / carer and relevant staff of the infection control protocol and waiting time 
associated with the garment modification. 
 It is the responsibility of the treating Occupational Therapist to determine alternative 
treatment strategies should the garment modification process take too long.  This may be 
particularly relevant for outpatients who live a long distance from RBWH.  Alternatives may 
include but are not limited to the following:- 
 Modification of 1 garment only, modification of 2nd garment at next outpatient 
appointment; 
 Elevation of limb until modified garment is ready; 
 Use of Coban or Handy gauze cohesive to apply pressure to the donor site while 
awaiting the garment. 
 
3. Modification of garments for inpatients and outpatients who have no MRO. 
 For patients who do not have MRO, garments that require modification on sewing machine 
or overlocker do not need to be washed first unless they are marked with strikethrough. 
 Strikethrough is contact of body fluid (blood, wound ooze or sweat).  Where strikethrough 
has wracked a garment item to be sewn, infection control and washing protocol is to be 
followed as per MRO procedure (section 2). 
(Infection Monitoring and Prevention Service (IMPS) RBWH) 2007 
 
2. Infection Control Procedure for provision and use of Elasticised Bike Pants  
   
Elasticised Bike Pants are;  
 
 - Stored and transported according to manufactures instructions for Tubigrip. 
 - Manufactured out of Tubigrip fabric, and are kept in clean protective packaging until provided to 
the patient, thereby reducing the risk of antimicrobial contamination. 
 - Provided to individual patients for their use only. 
 
 The Manufacturers (Molnlyke) instructions on the use of Tubigrip include; 
 
- In conjunction with or without wound care dressings  
- Following washing to ensure no loss of effectiveness of the elastic material. 
http://www.molnlycke.com/com/Wound-Care-Products/Product-selector---Wound-
division/Tabs/Products/Tubigrip-Elasticated-Tubular-Bandage/ 
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Essential Principle 9 - Construction and environmental properties  
 
9.1 Medical devices intended to be used in combination with other devices or equipment 
The elastic Tubigrip bike pants are not designed to be used in combination with another medical 
device or equipment. The use of the Tubigrip remains the same as intended by the manufacturer 
as specified on page 1 of this assessment. 
 
9.2 Minimisation of risks associated with the use of the medical device 
The known potential risks, or inconveniences associated with Pressure therapy may include 
discomfort from heat and perspiration, blistering, rash or scar breakdown.  These risks are known 
throughout the literature (Costa et al, 1999; Engrav et al 2007; Yildiz, 2007; Gibran, et al, 2007) and 
are commonly seen in every day practice with standard Pressure therapy garments. 
 
Essential Principle 10 - Medical devices with a measuring function  
 
Whilst the Elasticised Bike Pants provide a gentle compressive force on the limb, the Bike Pants 
themselves do not have a measuring function as such. The amount of pressure in each pair of Bike 
Pants is measured by placing a low profile air-filled pad between the garment and skin surface. 
This is a non-invasive procedure, and is measured with the Pico Press Pressure Sensor (Larsen, 
A. M., and Futtrup, I. 2004). 
 
Essential Principle 11 - Protection against radiation  
 
There is no radiation exposure associated with Elasticised (Tubigrip) Bike Pants. 
 
Essential Principle 12 - Medical devices connected to or equipped with an energy source  
 
Elasticised (Tubigrip) Bike Pants are not connected to or equipped with an energy source. 
 
Essential Principle 13 - Information to be provided with medical devices  
 
This section includes information regarding general information about the device 13.1, location of 
the information 13.2 provided under subclause 13.3 device requirements and instructions for use 
13.4. 
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EDUCATION HANDOUT 
 
Pressure Garments. Patient Education for Burn Injuries. Occupational Therapy 
 
What are Pressure garments? 
Pressure garments are used to help minimise scarring in new skin by softening, flattening and assisting skin 
to return to your normal colour.  
 
They also help by:  
- Protecting your skin as it heals; 
- Reducing skin itch 
- Reducing swelling; and 
- Supporting veins to allow good blood flow to and from your skin. 
 
There are many types of Pressure garments that may be prescribed for you through the healing stages. 
Depending on how mature your scar is, you may need to wear the garments for 1-2 years or longer. 
 
Your Occupational Therapist (OT) will review your scars and provide you with the most appropriate Pressure 
garments when you need them. Your OT will also teach you how to put your garments on and take them off 
correctly so that you do not damage your new skin.  
 
Your Pressure garments will be firm, but not too tight. Your OT will review the fit of your garments at your 
outpatient appointments. If you notice any of the following changes after wearing your garments, take them 
off and contact your OT: 
- Increased pain  
- Pins and needles 
- Throbbing 
- Numbness  
- Swelling.  
What type of Pressure garment is right for me? 
Soon after surgery, or when your burns are almost healed, you may be fitted with Tubigrip Pressure 
garments. These provide gentle Pressure to prepare your skin for stronger Pressure garments.  
 
As your skin is healing and your new skin becomes stronger, you may be fitted with firmer Pressure 
garments. These may be ‘ready made’ garments, or ‘custom-made’ garments. Your OT will measure and fit 
these for you depending on your needs.  
 
Pressure garments are made by many companies. The most suitable product will be different for each 
person and the choice of brand may be based on the size, location and severity of your scar; your individual 
body shape; and your daily activities and lifestyle.  
 s33634065  99 | P a g e  
 
How often do I wear my Pressure garments? 
Burns Pressure garments must be worn day and night, 23 out of 24 hours a day in order to help your new 
skin stay soft, flat and to help your skin return to your normal colour. 
 
Your garments may be removed for up to one hour per day to allow for showering, wound dressing changes, 
skin moisturisation and scar massage. Garments may be worn over wound dressings or silicone products. 
Ensure that your moisturising cream is well absorbed (wait 10-20 minutes) prior to reapplying silicone or 
garments. Make sure that your garments do not wrinkle up or down, and remain smooth throughout the day. 
 
How do I wash my Pressure garments? 
You will be provided with 2 garments to allow for daily wash & wear.   
Hand wash or gentle machine wash, inside a zip-up lingerie bag or pillow-case. Use lukewarm water with a 
neutral (low phosphate) detergent. Avoid use of bleach.  
 
Hang garments in the shade to dry.  Do not use a clothes drier, heater or hang in the sun as this can 
damage the properties of the elastic. 
 
If garments are well cared for they should last a minimum of six months.  The current policy of RBWH OT 
department is for 2 sets of garments every 6 months.  If you require garments more frequently than this, your 
OT can provide information regarding self purchase of additional garments. 
 
Garments range in price from $50 per pair for off-the-shelf garments, to $2000 per garment for custom made, 
so it is important to take good care of your garments.   
 
 
_____________________ 
Occupational Therapist 
Lvl 2 Dr James Mayne Bdg 
Ph:   3636 7100 
Fax: 3636 7495 
 
© The State of Queensland, Queensland Health, 2009 
Date Modified: December 2009  
Review Date:   December 2011 
 
 
HANDOUT, Recommendations and References 
 
Pressure may facilitate scar healing by decreasing blood flow and oedema while increasing 
collagen breakdown although these effects are poorly documented. 
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There is increasing evidence that fibroblasts respond to mechanical forces with signal transduction, 
alteration in collagen turnover, and remodelling. 
 
Pressure should be maintained between 24 and 30 mmHg for 6 to 12 months for this therapy to be 
effective. 
 
Effectiveness is related directly to the duration of pressure with a success rate of 85% in compliant 
patients. 
 
Correctly managed pressure therapy in combination with physiotherapy may minimise joint 
contracture and other deformities resulting from hypertrophic burn scars. 
 
 International Advisory Panel of Scar Management. 2001. International Recommendations on 
Scar Management. Chicago, USA. 
 
 Mallick, M., Carr, J. 1982, Manual on the management of the Burn Patient. Harmaville 
Rehabilitation Centre Educational Resource Division, Pittsburgh. 
 
 Pedretti, L., Early, M., 2001, Occupational Therapy. Practice Skills for Physical Dysfunction, 
(5th Edn). Mosby, Inc. Philadelphia. 
 
Essential Principle 14 - Clinical Evidence  
 
There is evidence in the literature to support the use of Pressure therapy to heal ‘Split 
Skin Grafts (SSG) in burns patients (Partsch, 2005; Ripper et al, 2009; Clark et al, 1996).  
However, specifically for the proposed use of Elastic Bike Pants for ‘Donor site healing’, 
there is only anecdotal evidence and case scenario information to suggest that Pressure 
therapy assists in this healing process. Pressure for donor site healing appears to be 
lacking in scientific evidence. 
 
Additionally, when a patient has been fitted with a Pressure garment for improved healing of a split 
skin graft site, the donor site has often been included in that Pressure garment. This is because the 
donor is sometimes anatomically close to the graft site, and to obtain adequate Pressure to the 
burned area, the donor site must be included (E.G. The SSG and donor site are on the same 
thigh).  
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It is with these situations that the following observation has been made; The known risks 
of Pressure (as listed in Essential Principle 6 above) appear the same in donor sites as 
those outlined for Split Skin Grafts. 
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APPENDICES C: Data collection forms 
Version 1.3                   15/03/2010 
APPENDIX C1 
 
 
 
 
 
 
Metro North - Royal Brisbane and Women’s Hospital – Occupational Therapy 
 
SIZING STUDY VOLUNTEER PARTICIPANT INFORMATION SHEET 
 
 
TITLE: Does compression therapy improve skin graft donor site scar maturation times in burns 
patients: A pilot investigation determining pressure to size ratio of Tubi grip bike pants. 
    
   
Please make sure you have read and understood all pages before signing the Consent or Assent Form to 
participate.  
 
Investigators: Ms Michelle Spermon, Occupational Therapy Department, Royal Brisbane and Women’s 
Hospital; Professor Michael Muller, Division of Surgery, Royal Brisbane and Women’s Hospital; Craig 
Readdy, Radiographer/Sonographer - Ultrasound Section 
Department of Medical Imaging, Royal Brisbane and Women’s Hospital; Dr Claire Simpson, Skin Culture 
Facility, Royal Brisbane and Women’s Hospital; Dr Joel Dulhunty, Division of Critical Care and 
Anaesthesiology, Royal Brisbane and Women’s Hospital; Dr Jennifer Paratz, Department of Intensive Care 
Medicine, Royal Brisbane and Women’s Hospital.  
 
1. Purpose of this form 
This Participant Information Sheet contains detailed information about the study. Its purpose is to explain to 
you as clearly as possible all the procedures involved in this study before you decide whether or not you 
would like to take part.  You may ask any questions that you might have, at any time about this document.  
Once you understand what the study is about and agree to take part, you will be asked to sign the Consent 
Form. By signing the Consent Form, you indicate that you understand the information and that you consent 
to participating in the research project.  You will be given a copy of the Participant Information Sheet to keep 
as a record. 
 
2. Background 
 
This Pilot study is a precursor to a clinical trial being held in the Adult Burns Unit.  
 
Compression Therapy has been used since the early 1970’s. It has been shown that compression therapy 
garments can help burns scars and grafts to heal by applying pressure to the burn with a firm stretchy 
garment. The garment is worn over any dressings that may be needed in the early stage of recovery. It is a 
well known treatment, but its effectiveness has not been scientifically assessed on donor site scars. For the 
purpose of this study, “Compression Therapy” will consist of wearing a pair of Tubigrip bike pants (otherwise 
known as a compression garment).  
 
Tubigrip bike pants are fabricated within the RBWH Occupational Therapy Department by Occupational 
Therapy Assistants. For the purpose of the proposed clinical trial the Tubigrip bike pants will be applied over 
the donor site and any dressings that are intact. They start at the waist and finish just above the knee. They 
will be worn in the same fashion as a pair of sports bicycle pants are worn by cyclists. Tubigrip Bike pants 
will provide a gentle compressive support to the healing donor site wound.  
 
What is a donor site? 
When a burn is deep into the skin it may require surgery to help it heal. Usually the surgery involves 
removing the burned or dead skin, and replacing it with a thin section of unburned healthy skin. A very thin 
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layer of healthy skin (or donor skin) is usually taken from the thigh area. The donor skin is then placed on the 
burnt area to help it heal. The area that is left on your thigh (where the doctor took the donor skin from) is 
called the ‘donor site’. It often looks and feels like gravel rash. In the short term, the new wound (donor site) 
can often add stress to your healing process.  
 
This study will assess whether or not compression therapy (see below) can improve donor site healing, and 
reduce the occurrence of thickened scarring of burn donor sites. 
 
3. Aim 
The aim of this study is to provide the following information;  
 
A) To determine a thigh/buttock/waist measurement (in centimetres) for fitting tubigrip bike pants into 
the following size ranges; extra small, small, medium, large, extra large. 
B) To determine a pressure range of 18 – 25 mmHg for each Tubigrip Bike pant size, in relation the 
thigh/waist/buttock measurement. 
 
This study is a baseline only.  
   
4. Study Procedure 
This study will require 15 minutes of your time to be measured for and fitted with a pair of tubigrip bike pants. 
A mock dressing will be positioned on your thigh to replicate the donor site dressings used in the burns 
patient population. A pressure sensor pad will be positioned under the garment on the thigh to determine the 
amount of pressure in the garment.  This will allow a baseline measure for the amount of pressure 
(measured in mmHg) applied to the thigh to be established. The pressure range proposed for this study is 
between 18 – 25 mmHg. This will establish a baseline size chart for the consistent fitting of the Tubigrip bike 
pants for the proposed clinical trial.  
 
5. Alternatives to Participation 
Alternative procedures involve not participating in this project.  
6. Risks and Benefits 
There should be little to no risk from your participation in this project. You will not gain any personal benefit 
from participating in this project, however more knowledge will be gained about the effectiveness of Tubigrip 
bike pants in the treatment of burns donor sites.  
7. New Information Arising During the Project 
During the research project, new information about the risks and benefits of the project may become known 
to the researchers. If this occurs, you will be told about this new information.  
8. Confidentiality 
The information gathered in this study, (computer files/paperwork) will be kept safely in a locked filing cabinet 
(only accessible by research staff).  The figures we record from you (e.g. thigh measurements) will be stored 
under a study number not an actual name. This data will be coded and can be potentially identifiable if 
needed. Any information obtained in connection with this project and that can identify you will remain 
confidential and will be stored in a locked office. It will only be disclosed with your permission, except as 
required by law. If you give us your permission by signing the Consent Form, we plan to publish the results in 
medical journals and present the information at conferences.  
If information from this project is published or presented in any public form personal details will not be 
released. Participant’s privacy and confidentiality will be respected at all times. A study number only will be 
used and the information is usually presented in journals or conferences as group data, for example an 
average of figures obtained rather than each patient’s results.  
No identifying information will be used in the data analysis.  All data will be appropriately destroyed 15 years 
following the completion of the project in accordance with NHMRC/AVCC Guidelines and Queensland 
Health’s Research Management Policy.   
 
9. Follow-up after the Study is completed 
You can choose whether or not you would like to be sent a short report at the completion of the study 
summarising the results.  We would greatly appreciate your participation in this research.  This research will 
help improve the management of patients with donor sites. 
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10.     Participation is Voluntary 
Participation in any research project is voluntary. If you do not wish to take part you are not obliged to. If you 
decide to take part and later change your mind, you are free to withdraw from the project at any stage. If you 
decide to withdraw from this project, please notify a member of the research team before you withdraw.  
Your decision whether to take part or not to take part, or to take part and then withdraw, will not affect your 
relationship with the Burns, Trauma and Critical Care Research Centre Royal Brisbane & Women’s Hospital. 
Before you make your decision, a member of the research team will be available to answer any questions 
you have about the research project. You can ask for any information you want.  Sign the Consent Form only 
after you have had a chance to ask your questions and have received satisfactory answers. 
11. Ethical clearance 
This study has been reviewed and approved by the Metro North - Royal Brisbane & Women’s Hospital 
Human Research Ethics Committee.  Should you wish to discuss the study with someone not directly 
involved, in particular in relation to matters concerning policies, information about the conduct of the study or 
your rights as a participant, or should you wish to make an independent complaint, you can contact the 
Coordinator or Chairperson, Human Research Ethics Committee, Royal Brisbane & Women’s Hospital, 
Herston, Qld, 4029 or telephone (07) 3636 5490. 
 
You are free to discuss your participation in this study with project staff (Ms Michelle Spermon in the 
Occupational Therapy Department at the Royal Brisbane and Women’s Hospital on (07) 3636 7100 or A/Prof 
Michael Muller in the Department of Surgery (07) 3636 1621 
 
This study adheres to the Guidelines of the ethical review process of The University of Queensland. Whilst 
you are free to discuss your participation in this study with project staff (contactable on 07 3636 7100), if you 
would like to speak to an officer of the University not involved in the study, you may contact the Ethics Officer 
on 3365 3924. 
 
The research is being conducted as part of Ms Michelle Spermon’s Masters of Philosophy degree through 
the University of Queensland. 
 
Thank you for your interest in this research project, 
 
Michelle Spermon     Prof Michael Muller  
Principal Researcher     Principal Supervisor 
(07) 3636 7100     
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APPENDIX C2 
Version 1.3           15/03/2010 
 
 
 
 
 
 
Metro North - Royal Brisbane and Women’s Hospital – Occupational Therapy 
 
SIZING STUDY STAFF PARTICIPANT CONSENT FORM 
 
 
TITLE: Does compression therapy improve skin graft donor site scar maturation times in burns patients: 
A pilot investigation determining pressure to size ratio of Tubi grip bike pants. 
 
 
Investigators: Ms Michelle Spermon, Occupational Therapy Department, Royal Brisbane and Women’s Hospital; 
Professor Michael Muller, Division of Surgery, Royal Brisbane and Women’s Hospital; Craig Readdy, 
Radiographer/Sonographer – Ultrasound Section, Department of Medical Imaging, Royal Brisbane and Women’s Hospital; 
Dr Clair Simpson, Skin Culture Facility, Royal Brisbane and Women’s Hospital; Dr Joel Dulhunty, Division of Critical Care 
and Anaesthesiology, Royal Brisbane and Women’s Hospital; Dr Jennifer Paratz, Department of Intensive Care Medicine, 
Royal Brisbane and Women’s Hospital;. 
 
I have read, and I understand the Participant Information version 2 dated 28/01/2010. 
I freely agree to participate in this project according to the conditions in the Participant Information.  
I will be given a copy of the Participant Information and Consent Form to keep  
The researcher has agreed not to reveal my identity and personal details if information about this project is published or 
presented in any public form.   
Participating Patients Name (printed)       ______ 
Signature       Date     ______ 
 
Name of Person giving Consent (printed)      ___________ 
Relationship to Participant:        ___________ 
 
Signature       Date     _____ 
 
Researcher’s Name (printed)        ______ 
Signature       Date     ______ 
Important: All parties signing the Consent Form must date their own signature. 
To be stored confidentially and separately from study information 
 
 
Australian New Zealand Clinical Trials Registry Number (ACTRN):12610000127000 
Royal Brisbane and Women’s Hospital Human Research Ethics Committee Approval No:HREC/09/QRBW/327 
University of Queensland Medical Research Ethics Committee Approval No:MREC2010000356 
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APPENDIX C2 continued 
Version 1.3   15/03/2010 
 
 
 
 
 
 
 
 
 
Metro North - Royal Brisbane and Women’s Hospital – Occupational Therapy 
 
PILOT STUDY 
 
STAFF REVOCATION OF CONSENT FORM 
 
 
TITLE: Does compression therapy improve skin graft donor site scar maturation times in burns patients: 
A pilot investigation determining pressure to size ratio of Tubi grip bike pants. 
 
 
Investigators: Ms Michelle Spermon, Occupational Therapy Department, Royal Brisbane and Women’s Hospital; 
Professor Michael Muller, Division of Surgery, Royal Brisbane and Women’s Hospital; Craig Readdy, 
Radiographer/Sonographer – Ultrasound Section, Department of Medical Imaging, Royal Brisbane and Women’s Hospital 
Dr Clair Simpson, Skin Culture Facility, Royal Brisbane and Women’s Hospital; Dr Joel Dulhunty, Division of Critical Care 
and Anaesthesiology, Royal Brisbane and Women’s Hospital; Dr Jennifer Paratz, Department of Intensive Care Medicine, 
Royal Brisbane and Women’s Hospital;. 
 
I hereby wish to WITHDRAW my consent to participate in the research proposal described above and understand that 
such withdrawal WILL NOT jeopardise any treatment or my relationship with Royal Brisbane & Women’s Hospital. 
 
Participating Patients Name (printed)       ______ 
Signature       Date     ______ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Australian New Zealand Clinical Trials Registry Number (ACTRN):12610000127000 
Royal Brisbane and Women’s Hospital Human Research Ethics Committee Approval No:HREC/09/QRBW/327 
University of Queensland Medical Research Ethics Committee Approval No:MREC2010000356 
 
 
 
 
 s33634065  108 | P a g e  
 
 
 
APPENDIX C3 
Version1.3 1 of 1 15/03/2010 
 
 
Metro North - Royal Brisbane and Women’s Hospital – Occupational Therapy 
 
Compression therapy and donor site scar maturation times in burns patients. 
 
DATA COLLECTION FORM 
 
         SIZING STUDY INTERVIEW SHEET 
 
       Date of Interview:________________ 
 
 
 
Signed consent given to participate in pilot:    Y  N 
         
Current Weight:__________Kg  Height:___________cm 
 
MEASUREMENTS Circumferences 
 
Waist: __________cm     Hip:_______cm   Abdomen (largest part):____________cm 
 
(R) knee______cm; +4 _______cm; +4 ________cm; +4________cm; +4_______cm 
 
+4 _______cm; +4 ________cm; +4________cm; +4_______cm (R) Top thigh _______cm 
 
(L) knee______cm; +4 _______cm; +4 ________cm; +4________cm; +4_______cm 
 
+4 _______cm; +4 ________cm; +4________cm; +4_______cm (L) Top thigh ________cm 
 
 
TUBIGRIP Bike pant size 
 
Size Pressure reading mmHg Objective Fit  Subjective Comfort Preference 
 
Ex- Small                     
   
 
Small                    
   
 
Medium           
   
 
Large      
   
 
Ex – Large    
   
 
Australian New Zealand Clinical Trials Registry Number (ACTRN):12610000127000 
Royal Brisbane and Women’s Hospital Human Research Ethics Committee Approval No:HREC/09/QRBW/327 
University of Queensland Medical Research Ethics Committee Approval No:MREC2010000356 
 
Patient Participation Number 
_______________ 
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APPENDIX C4 
Version1.3 1 of 5 15/03/2010 
 
 
 
 
 
 
Metro North - Royal Brisbane and Women’s Hospital – Occupational Therapy 
PILOT PARTICIPANT INFORMATION SHEET 
You are invited to participate in the following study: 
TITLE: Does Pressure therapy improve skin graft donor site scar maturation times in burns patients?
    
LAY TITLE:  Will Pressure therapy improve donor site scarring for burn patients? 
   
Please make sure you have read and understood all pages before signing the Consent or Assent Form to 
participate.  
 
Investigators: Ms Michelle Spermon, Occupational Therapy Department, Royal Brisbane and Women’s 
Hospital; Professor Michael Muller, Division of Surgery, Royal Brisbane and Women’s Hospital; Craig 
Readdy, Radiographer/Sonographer - Ultrasound Section 
Department of Medical Imaging, Royal Brisbane and Women’s Hospital; Dr Claire Simpson, Skin Culture 
Facility, Royal Brisbane and Women’s Hospital; Dr Joel Dulhunty, Division of Critical Care and 
Anaesthesiology, Royal Brisbane and Women’s Hospital; Dr Jennifer Paratz, Department of Intensive Care 
Medicine, Royal Brisbane and Women’s Hospital.  
 
1. Purpose of this form 
This Participant Information Sheet contains detailed information about the study. Its purpose is to explain to 
you as clearly as possible all the procedures involved in this study before you decide whether or not you 
would like to take part.  You may ask any questions that you might have, at any time about this document.  
Once you understand what the study is about and agree to take part, you will be asked to sign the Consent 
Form. By signing the Consent Form, you indicate that you understand the information and that you consent 
to participating in the research project.  You will be given a copy of the Participant Information Sheet to keep 
as a record. 
 
2. Background 
Pressure Therapy has been used since the early 1970’s. It has been shown that Pressure therapy garments 
can help burns scars and grafts to heal by applying pressure to the burn with a firm stretchy garment. The 
garment is worn over any dressings that may be needed in the early stage of recovery. It is a well known 
treatment, but its effectiveness has not been scientifically assessed on donor site scars. For the purpose of 
this study, “Pressure Therapy” will consist of wearing a pair of Tubigrip bike pants (otherwise known as a 
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Pressure garment). These garments are made from a stretchy elastic material (much like a normal pair of 
Lycra bike pants).They apply a gentle supportive pressure over the thigh and donor site areas.  
 
What is a donor site? 
When a burn is deep into the skin it may require surgery to help it heal. Usually the surgery involves 
removing the burned or dead skin, and replacing it with a thin section of unburned healthy skin. A very thin 
layer of healthy skin (or donor skin) is usually taken from the thigh area. The donor skin is then placed on the 
burnt area to help it heal. The area that is left on your thigh (where the doctor took the donor skin from) is 
called the ‘donor site’. It often looks and feels like gravel rash. In the short term, the new wound (donor site) 
can often add stress to your healing process.  
 
It is important to know that some donor sites will scar, and others will not. The whole process of taking skin 
and relocating it is called a split skin graft (or SSG for short).   
 
This study will assess whether or not Pressure therapy (see below) can improve donor site healing, and 
reduce the occurrence of thickened scarring of burn donor sites.  
 
3. Aim 
The aim of this study is to see if Pressure therapy is, or is not, beneficial in helping donor sites to heal.  
 
4. Study Procedure 
Participation in this project will involve you being randomly allocated to one of two groups. One group will 
receive (1) Pressure therapy and the other will receive (2) no Pressure therapy.  
 
Medical treatment (meaning surgical intervention, wound care dressings, medicines and nursing 
management) of the wound/burn/graft/donor or reconstructed area will be the same regardless of the group 
you are assigned. The only difference will be that one group will have Pressure therapy for their donor site, 
and the other will not.  
 
A standard brief history about the burn injury will be taken by the medical team, followed by a clinical 
examination and ongoing medical notes in your chart. The information used towards research from this 
history and ongoing medical notes will not identify you. It seeks information relating to: 
 
- your age, cause of injury, percentage body surface burned/wounded and depth of injury, grafting 
procedure undertaken, donor site location, medication used and time taken to heal (including 
number of dressing changes and types of dressings used).  
 
This information remains confidential and will not be accessed by any persons not directly involved in your 
care.    
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For the purpose of this study a Research Officer will interview you at day 5 following your surgery, and then 
every fortnight for a total of 12 weeks. (Every effort will be made by staff to have the research appointments 
match your follow up clinical appointments.)  
 
The researcher will assess the following items at these times for your donor site only; 
- The height, thickness, pliability, colour, pain and overall appearance of your donor site will be assessed 
using the Patient Observer Scar Assessment Scale or POSAS for short. The POSAS is an assessment 
tool that helps to gather certain information about your scar from the researcher’s opinion as well as the 
patient’s (your) opinion of the donor site. This involves rating 6 basic questions on a numerical rating 
scale. 
 
- After this has taken place the Principal Researcher will assist to prepare your donor site for some 
ultrasound measurements. The ultrasound scanning machine takes a picture (much like an x-ray) to 
produces an image of your scar. There will be 9 pictures in total taken of your scar. This allows the 
characteristics of your scar (like height, thickness, colour and how soft or hard your scar is) to be 
measured. 
 
- The ultrasound measurement will be carried out by another researcher who does not know if you have or 
haven’t had Pressure garment treatment. It is important not to say what treatment you are having during 
this time. The ultrasound should only take a few minutes and should be painless.  
 
- After that, your wound will be dressed by nursing staff as would be in a standard clinic.  
 
- If you are in the no Pressure therapy group you may leave once your dressings have been attended to. 
The same procedure will take place at your next appointment.  
 
- If you are in a Pressure therapy group the Principal Researcher will measure the amount of pressure in 
your garments and issue you with new garments if needed. You will then be free to leave until your next 
appointment, where the same procedure will take place.  
 
If you are the primary caregiver you will be able to accompany and support your son/daughter/minor at all 
stages of the procedure and research as with all as standard treatment. 
 
5. Alternatives to Participation 
If you choose not to participate in this study you will receive exactly the same standards of care / medical 
treatment (meaning surgical intervention, wound care dressings, medicines, allied health and nursing 
management) as all other patients. You may withdraw from the study at any stage without providing a reason 
and without influencing the medical treatment you receive at the hospital. 
 
6. Risks and Benefits 
Participation in the study is voluntary and can be declined without penalty of any kind.  You can withdraw 
from the study at any time.  Benefits of Pressure therapy may include improved appearance of the scar, 
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reduction of itch and pain, and prevention of skin contracture. The known potential risks, or inconveniences 
associated with Pressure therapy may include discomfort from heat and perspiration, blistering, rash or scar 
breakdown.   
There may be unknown side effects of donor sites treated with Pressure therapy as there have been no 
formal investigations of this therapy for donor sites. If an unknown side effect occurs, it will be addressed as 
standard current practice recommends, including reporting to the treating doctor, wound dressing 
management and removal of the garment until the problem has resolved. The risk of further therapy will then 
be assessed by the principal researcher in association with the treating doctor. 
 
We cannot guarantee that you will receive any benefits from this study.  
 
7. New Information Arising During the Project 
During the research project, new information about the risks and benefits of the project may become known 
to the researchers. If this occurs, you will be told about this new information. This new information may mean 
that you can no longer participate in this research. If this occurs, the person(s) supervising the research will 
stop your participation. In all cases, you will be offered all available care to suit your needs and medical 
condition. 
 
 
8. Confidentiality 
The information gathered in this study, (computer files/paperwork) will be kept safely in a locked filing cabinet 
(only accessible by research staff).  The figures we record from you (e.g. demographics, measurements, 
ultrasound images) will be stored under a study number not an actual name. This data will be coded and can 
be potentially identifiable if needed.  
Any information obtained in connection with this project and that can identify you will remain confidential and 
will be stored in a locked office. It will only be disclosed with your permission, except as required by law. If 
you give us your permission by signing the Consent Form, we plan to publish the results in medical journals 
and present the information at conferences.  
If information from this project is published or presented in any public form personal details will not be 
released. Participant’s privacy and confidentiality will be respected at all times. A study number only will be 
used and the information is usually presented in journals or conferences as group data, for example an 
average of figures obtained rather than each patient’s results.  
No identifying information will be used in the data analysis.  All data will be appropriately destroyed 15 years 
following the completion of the project in accordance with NHMRC/AVCC Guidelines and Queensland 
Health’s Research Management Policy.   
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9. Follow-up after the Study is completed 
You can choose whether or not you would like to be sent a short report at the completion of the study 
summarising the results.  We would greatly appreciate your participation in this research.  This research will 
help improve the management of patients with donor sites. 
 
10. Ethical clearance 
This study has been reviewed and approved by the Metro North - Royal Brisbane & Women’s Hospital 
Human Research Ethics Committee.  Should you wish to discuss the study with someone not directly 
involved, in particular in relation to matters concerning policies, information about the conduct of the study or 
your rights as a participant, or should you wish to make an independent complaint, you can contact the 
Coordinator or Chairperson, Human Research Ethics Committee, Royal Brisbane & Women’s Hospital, 
Herston, Qld, 4029 or telephone (07) 3636 5490. 
 
You are free to discuss your participation in this study with project staff (Ms Michelle Spermon in the 
Occupational Therapy Department at the Royal Brisbane and Women’s Hospital on (07) 3636 7100 or A/Prof 
Michael Muller in the Department of Surgery (07) 3636 1621 
 
This study adheres to the Guidelines of the ethical review process of The University of Queensland. Whilst 
you are free to discuss your participation in this study with project staff (contactable on 07 3636 7100), if you 
would like to speak to an officer of the University not involved in the study, you may contact the Ethics Officer 
on 3365 3924. 
 
The study is being conducted in the Professor Pegg Adult Burns Unit and the Specialist Outpatient Service 
at The Royal Brisbane and Women’s Hospital.  The research is being conducted as part of Ms Michelle 
Donovan’s Masters of Philosophy degree through the University of Queensland. 
 
Thank you for your interest in this research project, 
___________________________   ___________________ 
Michelle Donovan     Prof Michael Muller  
Principal Researcher     Principal Supervisor 
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APPENDIX C5 
Version1.3 1 of 2 15/03/2010 
 
 
 
 
 
Metro North - Royal Brisbane and Women’s Hospital – Occupational Therapy 
 
PILOT PARTICIPANT CONSENT FORM 
TITLE: Does Pressure therapy improve skin graft donor site scar maturation times in burns 
patients? 
 
LAY TITLE: Will Pressure therapy improve donor site scarring for burn patients?   
 
Investigators: Ms Michelle Spermon, Occupational Therapy Department, Royal Brisbane and Women’s 
Hospital; Professor Michael Muller, Division of Surgery, Royal Brisbane and Women’s Hospital; Craig Readdy, 
Radiographer/Sonographer – Ultrasound Section, Department of Medical Imaging, Royal Brisbane and 
Women’s Hospital; Dr Claire Simpson, Skin Culture Facility, Royal Brisbane and Women’s Hospital; Dr Joel 
Dulhunty, Division of Critical Care and Anaesthesiology, Royal Brisbane and Women’s Hospital; Dr Jennifer 
Paratz, Department of Intensive Care Medicine, Royal Brisbane and Women’s Hospital;. 
 
1. I acknowledge that I have read the information sheet provided, and that I have had the project, (so far 
as it affects me), fully explained to my satisfaction by the investigators. I freely consent to my participation 
in the project. 
2. I understand that the primary purpose of this research is to determine if Pressure therapy improves the 
quality of donor site healing for people who have undergone split thickness skin grafting following a burn 
injury.   
3. I understand that the research involves assessments at fortnightly intervals for a period of 3 months. I 
will undertake these assessments as a patient of the Professor Pegg Adult Burns Unit and then as an 
Outpatient in Royal Brisbane and Women’s Hospital Burns Clinic. 
4. I understand that I will be required to rate my scar at various stages of treatment by marking a series of 
boxes on an assessment form. 
5. It has been explained to me that this is a research project and not a separate treatment program, and 
my involvement may not be of any direct benefit to me. 
6. I have taken the opportunity to have a member of my family or a friend present where possible, while 
the project was explained to me. 
7. I give my permission to the above investigators to access my medical records for the purpose of this 
research.  
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8. I am informed that no information regarding my medical history will be divulged. The results of my 
evaluation will not be published to reveal my identity, and that this will not affect in any way the ongoing 
treatment of my condition. 
9. I understand that I am free to withdraw from the project at any stage and that this will not affect the 
ongoing treatment of my condition. 
10. I understand that the data from this project will be kept securely in the Division of Occupational Therapy 
at the Royal Brisbane Hospital. 
11. My consent is given on the understanding that the research study will be carried out in a manner 
conforming to the principles set out by the Declaration of Helsinki, the National Health & Medical 
Research Council, and the Australian Guidelines for Good Clinical Research practice. 
12. The study has been approved by the Research Ethics Committee, Royal Brisbane Hospital and Royal 
Women’s Hospital Health Districts. 
13. The University Of Queensland School Of Medicine Post Graduate Research Committee has approved 
this study.  
 
I wish to receive the final outcomes of this study (please circle) Yes   /No  
email:_________________________________________________________________________________ 
Participating Patients Name (printed)       _____________________ 
Signature       Date    _____________________ 
Name of Person giving Consent (printed)      _____________________ 
Relationship to Participant:       ___________________________ 
 
Signature       Date    _____________________ 
Researcher’s Name (printed)        _____________________ 
Signature       Date   ____________________________ 
 
Important: All parties signing the Consent Form must date their own signature. 
To be stored confidentially and separately from study information 
Thank you for your interest in this research project,  
 
_________________     __________________ 
Michelle Donovan      Prof Michael Muller  
(07) 3636 7100      (07) 3636 1621 
Principal Researcher     Principal Supervisor 
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APPENDIX C6 
Version1.3 1 of 1 15/03/2010 
 
 
 
 
 
 
 
 
Metro North - Royal Brisbane and Women’s Hospitals – Occupational Therapy 
 
Compression therapy and donor site scar maturation times in burns patients. 
 
PILOT PARTICIPANT INTERVIEW SHEET  
 
DATA COLLECTION FORM 
 
Date of Interview:_____________Participant Number:______________ Date of Injury ________ 
        
Date of Surgery (Split Skin Graft) ____________ Donor depth____________TBSA ___________ 
 
Current Weight:_________Kg.  Height_____________cm BMI:________________ 
 
Age: __________      Erythema: _______________    _______________ 
 
DONOR SITE MAP 
 
DONOR SKIN 
 
                                                                  
(1)____________mm            (2)____________mm            (3)___________mm 
 
                                   
                                   
NORMAL SKIN MAP COMPARISON (same leg) 
 
NORMAL SKIN 
 
 
  10) _____________mm      11)_____________mm       12)____________mm 
 
Clinical Utility of ULTRASOUND:   
 
Time for set up _____________________ 
 
Time for initial assessment ___________________      repeat assessment __________________ 
 
Number of times required to reload device ____________________ 
Number of times to capture a clear image _____________________ 
 
Format – Acceptability to the patient Y / N  Impacting Factors? ___________________ 
               Acceptability to the clinician Y /N  Impacting Factors?__________________ 
 
Australian New Zealand Clinical Trials Registry Number (ACTRN):12610000127000 
Royal Brisbane and Women’s Hospital Human Research Ethics Committee Approval No:HREC/09/QRBW/327 
University of Queensland Medical Research Ethics Committee Approval No:MREC2010000356 
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APPENDIX C7 
 
The Fitzpatrick Skin-Type Chart 
Add up the score for each of the questions answered.  At the end there is a scale providing a range 
for each of the six skin-type categories.  Following the scale is an explanation of each of the skin 
types.   
  
Genetic Disposition 
Score   0   1   2   3   4  
What is the colour of your eyes?    Light 
blue, Grey, Green   
Blue, Grey or 
Green   
Blue   Dark Brown   Brownish 
Black  
What is the natural colour of your 
hair?   
Sandy Red   Blond   Chestnut/Dark Blond   Dark Brown   Black  
What is the colour of your skin (non 
exposed areas)?   
Reddish   Very Pale   Pale with Beige tint   Light Brown   Dark Brown  
Do you have freckles on unexposed 
areas?   
Many   Several   Few   Incidental   none  
 
Total score for Genetic Disposition: _____  
Reaction to Sun Exposure  
Score   0   1   2   3   4  
What happens when you stay 
in the sun too long?   
Painful redness, 
blistering, peeling   
Blistering followed 
by peeling   
Burns sometimes 
followed by peeling  
Rare  
 burns   
Never had 
burns  
To What degree do you turn 
brown?   
Hardly or not at all   Light colour tan  Reasonable tan   Tan very easy   Turn dark 
brown quickly  
Do you turn brown within 
several hours after sun 
exposure?   
Never   Seldom   Sometimes   Often   Always  
How does your face react to 
the sun?   
Very sensitive   Sensitive   Normal   Very 
resistant   
Never had a 
problem  
 
Total score for Reaction to Sun Exposure: _____ 
Tanning Habits  
Score   0   1   2   3   4  
When did you last expose your body to sun (or 
artificial sunlamp/tanning cream)?   
More than 3 
months ago   
2-3 months 
ago   
1-2 months 
ago   
Less than a 
month ago   
Less than 2 
weeks ago  
Did you expose the area to be treated to the 
sun?   
Never   Hardly ever   Sometimes   Often   Always  
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Total score for Tanning Habits: _____  
   
Add up the total scores for each of the three sections for your Skin Type Score.  
Skin Type Score - Fitzpatrick Skin Type  
0-7  I  
8-16  II  
17-25  III  
25-30  IV  
over 30  V -VI  
  
TYPE 1: Highly sensitive, always burns, never tans. Example: Red hair with freckles  
TYPE 2: Very sun sensitive, burns easily, tans minimally. Example: Fair skinned, fair haired 
Caucasians  
TYPE 3: Sun sensitive skin, sometimes burns, slowly tans to light brown. Example: Darker 
Caucasians.  
TYPE 4: Minimally sun sensitive, burns minimally, always tans to moderate brown.  
                 Example: Mediterranean type Caucasians, some Hispanics.  
TYPE 5: Sun insensitive skin, rarely burns, tans well. Example: Some Hispanics, some Blacks  
TYPE 6: Sun insensitive, never burns, deeply pigmented. Example: Darker Blacks.  
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APPENDIX C8 
 
POSAS Observer scale 
The Patient and Observer Scar Assessment Scale  v2.0 / EN 
 
 
 
Explanation 
The observer scale of the POSAS consists of six items (vascularity,  pigmentation, thickness, relief, pliability and surface area). All items are scored on a scale 
ranging from 1 (‘like normal skin’)  to 10 (‘worst scar imaginable’). 
The sum of the six items results in a total score of the POSAS observer  scale. Categories boxes are added for each item. Furthermore, an overall  opinion is scored on a 
scale ranging from 1 to 10. All parameters should preferably be compared to normal skin on a  comparable anatomic location. 
Explanatory notes on the items: 
• vascularity  Presence of vessels in scar tissue assessed by the amount of redness, tested by the amount of blood return after blanching with a  piece of 
Plexiglas 
• pigmentation  Brownish coloration of the scar by pigment (melanin); apply Plexiglas to the skin with moderate pressure to eliminate the  effect of 
vascularity 
• thickness  Average distance between the subcutical-dermal border and the epidermal surface of the scar  
• relief  The extent to which surface irregularities are present  
(preferably compared with adjacent normal skin) 
• pliability  Suppleness of the scar tested by wrinkling the scar between the thumb and index finger surface area  Surface area of the scar in relation to 
the original wound area        copyright © p.p.m. van zuijlen, beverwijk-nl 
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APPENDIX C9 
 
POSAS Patient scale  
The Patient and Observer Scar Assessment Scale  v2.0 / EN 
  
 
 
 
 
copyright © p.p.m. van 
zuijlen, beverwijk-nl 
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APPENDIX D: Research Ethics Approval 
 
APPENDIX D1: RBWH Human Research Ethics Approval 
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APPENDIX D2: University of Queensland Human Research Ethics Approval 
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APPENDIX D3: Private Practice Trust Fund Grant Award 
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APPENDIX D4: Site specific approval 
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APPENDIX D5: Data custodian approval 
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APPENDIX E: Other relevant information 
 
APPENDIX E1: Dermascan C® Training Certificate 
